Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

AECI

AECI Ltd

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | AECI Limited | SENS FY2025 | | Former names | African Explosives and Industries Ltd (1924), later African Explosives and Chemical Industries (AE&CI). | Company heritage | | Founding year | 1896, the origins of the Modderfontein explosives works. The company was registered in 1924. | Company profile; CB Insights (1896) | | Incorporation jurisdiction | Republic of South Africa | SENS | | Registration number | 1924/002590/06 | SENS | | Headquarters / registered office | First Floor, AECI Place, 24 The Woodlands, Woodlands Drive, Woodmead, Sandton, 2191, South Africa | SENS FY2025; website | | Primary listing | JSE, ordinary shares, code AFE, listed 1966 | Company profile; Profile's Handbook | | Other listed instruments | 5.5% cumulative preference shares, JSE code AFEP; JSE-listed debt (bond company code AECI) | SENS | | ISIN (ordinary) | ZAE000000220 | SENS | | ISIN (preference) | ZAE000000238 | SENS | | CUSIP | Not publicly disclosed (no US listing identified) | — | | LEI | 3789008641F1D3D90E85 | SENS | | Listed subsidiary | AECI Mining Explosives Plc, Lusaka Securities Exchange (Zambia), ISIN ZM0000000284 | LuSE SENS, 28 Aug 2026 | | Fiscal year end | 31 December | SENS | | Ordinary shares in issue | 105,517,780 (plus 3,000,000 listed cumulative preference shares) | Interim results H1 2026 | | Employees (latest) | 5,341 at 30 Jun 2026 | Interim results H1 2026 | | Employees (trend) | ~7,600 (2023, third-party citing company); 7,189 and 6,938 (Profile's Handbook editions, headcount date not stated); 5,459 (31 Dec 2025); 5,341 (30 Jun 2026) | Various; see 1.2 | | External auditor | Deloitte & Touche (review partner MLE Tshabalala for FY2025) | SENS FY2025 review report | | Equity sponsor | One Capital Sponsor Services (Pty) Ltd | SENS | | Debt sponsor | Questco (Pty) Ltd | SENS | | Transfer secretaries | Computershare Investor Services (Pty) Ltd (SA) and Computershare Investor Services PLC (UK) | SENS | | Market capitalisation | About R11.08bn at a share price of R108.44 on 19 Aug 2026 (MarketScreener). | MarketScreener | | Countries of operation | "Over 20 countries on six continents" (company); 22 countries (Profile's Handbook) | Interim results H1 2026; Profile's Handbook 2026 | | Metric | FY2023 | FY2024 | FY2025 | H1 2026 | |---|---|---|---|---| | Employees (number) | 7600 | 7189 | 5459 | 5341 | Notes: - The FY2023 figure (~7,600) comes from a third-party summary (TradingView) citing company disclosure. - The FY2024 figure (7,189) is taken from Profile's Stock Exchange Handbook 2025 Issue 3/4, which does not state the headcount date. - FY2025 and H1 2026 are company-reported. - The roughly 28% reduction since 2023 mainly reflects disposals: Much Asphalt, Schirm USA, Baar-Ebenhausen and Food & Beverage. AECI is a 130-year-old South African industrial group. Its portfolio has been deliberately narrowed from a sprawling chemicals conglomerate into two businesses: a mining services business, and a predominantly South African specialty and industrial chemicals business. AECI Mining contributed about 55% of FY2025 revenue and about 80% of segment EBITDA before corporate costs. It supplies bulk and packaged explosives, initiating systems (including electronic detonators), blasting services, emulsifiers and mining chemicals across Southern Africa, the rest of Africa and Asia-Pacific. It competes with Orica, Dyno Nobel, Enaex and Omnia's BME. AECI Chemicals serves industrial, water-treatment and agricultural customers, mainly in South Africa. After a 2023–2025 restructuring that raised about R2.2bn from disposals in 2025 alone, the group has: - record EBITDA (R3.4bn in FY2025); - near-zero net debt at year-end 2025 (R465m); - ROIC of 13%, against a 17–21% target. A new CEO, Alan Dickson (formerly Reunert CEO), took office on 1 July 2026. His task is to convert a cleaner portfolio into consistent, margin-led growth. --- ### What the company does — company description In its H1 2026 interim results, AECI describes itself as a 101-year-old diversified group serving mining, infrastructure and industrial customers. It counts from the 1924 registration; elsewhere it dates its origins to 1896. Its offering covers high-performance explosives, initiating systems, blasting services, mining chemicals and tailored specialty chemical solutions. The stated purpose is "We Are One AECI, for a Better World". From H1 2026 the group reports three segments: **AECI Mining:** a global mining services business. It provides integrated mine-to-mineral offerings, from commercial explosives, initiating systems, blasting services and explosive-manufacturing surfactants through to chemicals for ore beneficiation and tailings treatment. **AECI Chemicals:** a predominantly South African provider of specialised solutions for the industrial, water and agricultural sectors. It supplies traded, industrial and specialty chemicals, water treatment solutions, crop protection products and plant nutrients. Since 2026 it also includes the residual "Managed Businesses", which serve the animal nutrition and textile sectors. **AECI Property Services and Corporate:** property leasing and management in the office, industrial and retail sectors, plus shared utilities and services (notably at the Umbogintwini Industrial Complex in KwaZulu-Natal) and central corporate functions. ### Independent characterisation AECI is best understood as a mid-tier global commercial explosives and mining chemicals company with an attached South African chemicals distribution and manufacturing business. Its economics are driven by four things: 1. **Ammonia/ammonium-nitrate-linked explosives volumes.** These are sold under multi-year contracts to miners, increasingly with cost pass-through. AECI notes that sourcing costs are now linked to contract pricing (FY2025 SENS). 2. **Manufacturing reliability at Modderfontein.** This is the flagship South African initiating systems and explosives site. Power interruptions and ammonia and lead azide supply disruptions there depressed FY2025 detonator volumes. 3. **Geographic expansion** into higher-margin Asia-Pacific (Australia, Indonesia, Papua New Guinea) and African copper and gold belts (DRC, Zambia, Ghana, Mali, Burkina Faso). 4. **A low-margin, working-capital-heavy South African chemicals book.** It converts cash well (133% free cash flow conversion in FY2025) but earns EBITDA margins of only about 7–9%. ### Business model and revenue model mix | Revenue type (FY2025, continuing ops) | AECI Mining (R m) | AECI Chemicals (R m) | Managed Businesses (R m) | Property & Corporate (R m) | |---|---|---|---|---| | Sale of goods | 16159 | 8303 | 3996 | 0 | | Sale of goods and related product application services | 1463 | 2003 | 0 | 0 | | Sale of services | 0 | 0 | 0 | 572 | | Rental income | 0 | 0 | 0 | 126 | Source: FY2025 reviewed results, note 2. Inter-segment eliminations of R439m are excluded. Interpretation: - About 89% of revenue is product sales. - About 11% is product-plus-application-service revenue (blasting services, water treatment services). - Property leasing and services are under 2%. - There is no material subscription or licensing revenue. AECI does receive licence fees from foreign subsidiaries, which attract foreign withholding taxes (FY2025 tax note). ### Value chain position **Upstream inputs:** ammonia (imported and local; AECI built an ammonia import supply chain in South Africa and imported about 10,000 tonnes in 2025, per the 2025 Integrated Report summary), ammonium nitrate, lead azide, fuel oils, surfactants and commodity chemicals. **Midstream:** manufacture of emulsions, packaged explosives, initiating systems, emulsifiers, flotation and flocculant reagents, and formulated chemicals. **Downstream:** on-mine bulk delivery, charging and blasting services; technical service for reagent dosing; water treatment engineering. ### Customer types and end-markets | End-market | Exposure | Evidence | |---|---|---| | Hard-rock and open-pit mining (gold, copper, PGMs, iron ore, coal) | Core of AECI Mining | FY2025 / H1 2026 segment commentary | | Phosphate rock and energy-transition minerals | Mining chemicals (flocculants, reagents) | Interim CEO Dean Murray, Engineering News, 25 Feb 2026 | | Quarrying and construction | Explosives (minor, not separately disclosed) | — | | Industrial manufacturing | Industrial and Specialty Chemicals | FY2025 SENS | | Public and industrial water | Water business (ImproChem) | FY2025 SENS | | Agriculture | Plant Health (crop protection, plant nutrients), including Malawi | FY2025 SENS | | Animal nutrition, textiles | Residual Managed Businesses (Animal Health, SANS Technical Fibers) | H1 2026 SENS | | Real estate tenants | Property Services | FY2025 / H1 2026 SENS |

Revenue$1.8B
Employees5,341
Market Cap$0.6B
Founded1924
Sandton, South Africa

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
ADXEnergy

ADX Energy Ltd

Premium
Information Technology

ADX Energy is a Perth-headquartered, Vienna-operated micro-cap exploration and production company whose entire revenue base sits in Austria. It owns and operates 100% of the mature Gaiselberg and Zistersdorf oil and gas fields in the Vienna Basin, acquired from RAG Austria in 2019, and operates the Anshof oil field in Upper Austria (70% economic interest), which it discovered in 2022. Around this modest production base of roughly 200–270 BOEPD, ADX has assembled outsized exploration leverage: the Welchau carbonate discovery (387 BCF gas plus 31 MMBBL liquids mean prospective resource, 75% interest), a shallow biogenic-gas drilling program in Upper Austria that delivered the HOCH-1 discovery in 2026, and the 100%-owned C.R150.AU gas permit offshore Sicily (619 BCF mean prospective resource). The equity story is a European energy-security gas play funded by farm-outs, small placements and production cash flow, with heavy dilution and funding risk as its principal counterweight. --- ### What the company does ADX Energy's principal activities, as described in the FY2025 Directors' Report, are oil and gas production, appraisal and exploration. In practice the business has three layers: 1. **Producing assets (cash flow base).** The Vienna Basin Fields (Gaiselberg and Zistersdorf, 100% working interest, operated) and the Anshof Field in Upper Austria (70% economic interest in the field area and Anshof-3, 60% in the Anshof-2A well, operated). Crude oil is sold into the European market (historically including a pipeline route to the Schwechat refinery near Vienna, per the 2020 investor material), Anshof crude is trucked to a nearby rail loading facility, and Vienna Basin associated gas is sold into the pipeline network. Net Austrian production averaged approximately 248 BOEPD in FY2025 versus 211 BOEPD in FY2024. 2. **Low-risk, near-infrastructure exploration (growth engine).** A Shallow Gas Program targeting biogenic (≈99% methane) Miocene Hall Formation sandstones in the ADX-AT-I and ADX-AT-II licences; a near-field oil program around the Anshof Permanent Production Facility (PPF), whose capacity is about 3,000 BPD against current throughput of roughly 100 BOPD gross. 3. **High-impact exploration (option value).** The Welchau anticline (fractured Triassic carbonates, gas-condensate plus updip light oil), sub-Flysch gas prospects, and the offshore Sicily Channel C.R150.AU gas permit in Italy. A legacy Romanian position (49.18% of Danube Petroleum, holding the Iecea Mare production licence and the now-expired Parta exploration licence) remains, but is now principally a dispute/contingent liability rather than a growth asset. ### Business and revenue model | Revenue component | Description | Share of revenue | |---|---|---| | Crude oil sales | Vienna Basin and Anshof crude, priced off Brent; largely unhedged except tactical collars (e.g., April–July 2025 collar on 3,000 bbl/month) | Majority — exact split not disclosed; crude was 99,288 bbl of 103,961 BOE gross sold in FY2025 (≈95.5% of volume) | | Gas sales | Vienna Basin associated gas sold to pipeline; Anshof associated gas used on site for power/heat | 4,673 BOE gross sold in FY2025 (≈4.5% of volume) | | Partner contributions | Cost recoveries from farm-in partners (MND, MCF, Empyrean) — recorded against capital/expense rather than as revenue | Not revenue; FY2025 receipts of EUR 302,622 (development) and EUR 221,797 (exploration/operating) | | Product / service / subscription / licensing mix | Not applicable — ADX is a pure commodity producer (100% product revenue) | 100% product | The company is positioned at the upstream end of the value chain only: it explores for, develops and produces hydrocarbons, and sells them at the field gate or export inlet. It owns modest midstream infrastructure (Vienna Basin processing facilities, storage tanks, a pipeline connection, and the Anshof PPF, purchased from lessor ONEO GmbH in late 2025), but does not refine or market to end users. **Customer types and end-markets.** Customers are refiners/crude purchasers and gas buyers in Austria and the broader Central European market. Specific counterparties are not publicly disclosed in the documents reviewed. The end-markets served are the European crude oil market (Brent-linked) and the Austrian/Central European natural gas market (TTF-linked; Italian PSV for any future Sicily Channel production). ### Company's own description vs. independent characterisation In its FY2025 Annual Report, management frames ADX as holding long-life, stable oil production, low-risk "fast track" exploration and high-impact exploration assets held at high equity levels, all within "low risk, high value markets" that need domestic supply. The Chairman's report emphasises a portfolio pivot toward gas (79% of the combined mean prospective resource inventory) to benefit from European undersupply and LNG dependence. **Independent characterisation.** ADX is better described as an exploration company with a small, ageing production base that roughly covers field operating costs but not corporate overhead, exploration expense and capital spending. In FY2025 operating revenue of A$10.79 million was almost entirely consumed by A$9.69 million of operating costs, before A$3.56 million of depreciation and A$3.70 million of exploration expensed. The investment case therefore rests almost entirely on converting exploration resources (shallow gas at HOCH/GOLD/SCHOE, Welchau, Sicily) into reserves and cash flow before balance-sheet constraints force further dilutive raisings. The company's gas-weighted European positioning is genuinely differentiated among ASX micro-caps, but the scale of its prospective resources (253 MMBOE net mean, unrisked) is very large relative to its A$20 million market value — a gap that reflects high geological, permitting and funding risk.

Revenue$0.0B
Employees4
Market Cap$0.0B
Founded1983
Stirling, United Kingdom
Adveritas

Adveritas Limited

Premium
Information Technology

Adveritas is a Perth-based advertising-technology company whose sole commercial product, TrafficGuard, is an AI-driven software-as-a-service platform that detects, blocks and reports invalid traffic (IVT) and ad fraud across paid search (Google Ads), paid social (Meta), mobile app user-acquisition, programmatic and affiliate channels. Unlike the large ad-verification incumbents (DoubleVerify, Integral Ad Science), which concentrate on brand-safety and viewability measurement for large brand advertisers in programmatic display and CTV, TrafficGuard focuses on performance marketers — advertisers who pay per click, per install or per conversion and therefore lose money directly to bots and fraudulent clicks. The company's commercial traction is concentrated in North American sports betting and online gaming (named customers include FanDuel and Bally's), with expansion into agencies, eCommerce, retail and, since April 2026, a self-serve SME tier. Annualised recurring revenue (ARR) reached A$16.65M at 30 June 2026, but the company remains loss-making and dependent on periodic equity raises. --- ### What the company does Adveritas sells TrafficGuard, a fraud-prevention and traffic-verification platform for digital advertisers. When an advertiser buys digital media on a cost-per-click (CPC), cost-per-install (CPI) or cost-per-action (CPA) basis, a material share of clicks and installs can be generated by bots, click farms, competitors, malicious publishers or affiliates engaging in attribution fraud (click injection, click spamming, install hijacking). TrafficGuard ingests click, impression, install and conversion data, scores each interaction using machine-learning models, and either blocks the invalid traffic before budget is spent (e.g., by excluding IPs, placements or audiences in Google Ads and Meta campaigns) or flags it for reconciliation and refund claims with ad networks and affiliates. The company's own description (as reproduced by Morningstar from company filings) characterises Adveritas as an advertising technology company whose principal activity is the provision of TrafficGuard SaaS products, described as a full-funnel measurement, verification and fraud-prevention solution for digital advertising. ASX releases from 2025–2026 describe Adveritas as a "global digital marketing anti-fraud specialist" leveraging big data and AI (Source: ASX releases 19 June 2025; 17 October 2025). ### Business and revenue model | Revenue element | Description | Mix | |---|---|---| | Enterprise SaaS subscriptions | Annual or multi-year contracts, priced on the volume of traffic/ad spend protected; many customers prepay annual fees to secure better pricing (Source: HY Dec 2024 Appendix 4D) | Majority of revenue (exact split not publicly disclosed) | | Agency partnership contracts | Contracts with media agencies that deploy TrafficGuard across multiple advertiser clients; first Tier-1 agency contract signed FY2025, adding c. A$0.5M ARR (Source: FY2025 Annual Results, 28 Aug 2025) | Not separately disclosed | | Self-serve / SME subscriptions | Automated sign-up tier for Google and Meta advertisers; relaunched 1 April 2026; 1,002 sign-ups and 89 paying accounts by the June 2026 quarter (Source: June 2026 Quarterly Activities Report, 31 Jul 2026) | Small but growing; self-serve customer revenue up 59% in the year to March 2026 (Source: ASX release 1 Apr 2026) | | Marketplace contracting | TrafficGuard is listed on the Google Cloud Marketplace, allowing clients to contract and pay through Google Cloud | Not separately disclosed | The model is effectively 100% subscription/software; there is no hardware, licensing-for-resale or professional-services revenue of significance disclosed. Revenue is recognised over the contract term, and the prepayment of annual fees creates a sizeable contract-liability (deferred revenue) balance — which explains why cash receipts (A$10.38M in FY2025) exceeded recognised revenue (A$7.84M) and why net tangible assets per share turned negative (–0.04 cents) at 30 June 2026 despite no material debt. ### Value-chain position TrafficGuard sits between the advertiser (or its agency) and the media sellers (Google, Meta, ad networks, affiliates, programmatic exchanges). It is an independent third-party verifier — it does not sell media and has no incentive to inflate traffic. It integrates with mobile measurement partners (MMPs), ad platforms' APIs (Google Ads, Meta, following Meta's approval of the integration in 2025) and affiliate-network tracking. ### Customer types and end-markets | Vertical | Commentary (source) | |---|---| | Sports betting & online gaming (North America) | Largest contributor to ARR; named customers include FanDuel and Bally's, with combined annual contract values of c. A$1.1M disclosed in HY Dec 2024 (Source: Appendix 4D, 25 Feb 2025). Short sales cycles and very high customer-acquisition budgets | | Agencies | Strategic channel since FY2025; ARR from agencies grew strongly in HY Dec 2025 (Source: HY Dec 2025 results, 27 Feb 2026) | | eCommerce & retail | Identified as growth verticals in FY2025–FY2026 (Source: FY2025 results; trading update 26 May 2026) | | Affiliate programmes | Several affiliate agreements signed in the September 2025 quarter subject to trials (Source: Q1 FY2026 4C, 17 Oct 2025) | | SMEs (self-serve) | Targeting over 200 million SME digital advertisers globally (company estimate, ASX release 1 Apr 2026) | | Historical: super-apps / mobile UA | Early adopters included LATAM super-app Rappi and APAC super-app GO-JEK (Source: company profile on Stockhead) | ### Independent characterisation Adveritas is a single-product, sub-scale SaaS vendor that has found product-market fit in a niche (performance-marketing fraud for regulated North American betting operators) and is attempting to broaden into horizontal markets. Its unit economics appear to be improving: revenue more than doubled between FY2024 and FY2026 while operating cash outflow fell from A$9.2M (FY2024) to A$2.9M (FY2025). However, FY2026 cash consumption re-accelerated (cash fell from A$9.48M to A$4.49M), ARR growth decelerated from 91% (March 2026) to c. 59–60% (June 2026), and FY2026 revenue (A$10.31M) fell short of the broker consensus of c. A$11.5M recorded by MarketScreener. The investment case therefore hinges on whether the self-serve SME channel and agency partnerships can scale without another dilutive raise.

Revenue$0.0B
Employees11
Market CapN/A
Founded2017
Bentley, Australia
Advanced

Advanced Human Imaging Limited

Premium
Information Technology

Advanced Health Intelligence is a small Perth-based digital-health software developer. It sells smartphone-based biometric health screening to businesses. The technology combines a patented on-device body-dimensioning engine (BodyScan) with licensed facial blood-flow vital-signs technology (FaceScan, licensed from NuraLogix) and licensed AI dermatology (DermaScan, licensed from Triage Technologies). Together these form a "Biometric Health Assessment" (BHA) that estimates cardiometabolic risk, blood biomarkers and fitness. AHI sells this to insurers, telehealth platforms, pharmacies, employers and governments, either as a white-label product or as embeddable SDKs, under a "Digital Health as a Service" model. The company has a credible IP base: 19 granted patents at FY2023. Commercial traction, however, has been minimal. Operating revenue was A$0.37M in FY2024 (unaudited), and the business has relied on R&D tax refunds and repeated dilutive raises. A sequence of failures to keep its listings has left it as an unlisted company: Nasdaq equity-deficiency delisting in 2024, then ASX removal in 2025 after the FY2024 accounts were never lodged. It is now a distressed, pre-scale health-tech asset. --- ### What the company does AHI develops software that turns a standard smartphone into a health-screening device. According to its FY2023 Form 20-F (Item 4B) and FY2024 Appendix 4E, its core offerings are: 1. **Body dimension and composition assessment.** A full-body "selfie" (front and side images) estimates circumferences, body-fat percentage, waist-to-hip and waist-to-height ratios, and risk of obesity, central obesity and Type 2 diabetes. 2. **Blood biomarker prediction.** Algorithms estimate total cholesterol, LDL, HDL, triglycerides, HbA1c, C-reactive protein, fasting glucose and 10-year cardiovascular/mortality risk. These came largely from the August 2022 Vertica Health acquisition. 3. **Transdermal Optical Imaging (TOI).** A 30-second facial video estimates heart rate, heart-rate variability, blood pressure, respiration and stress. This uses technology licensed from NuraLogix Corporation and its DeepAffex cloud engine. 4. **On-device dermatological identification.** The engine covers 588 skin conditions across 133 categories, including melanoma, and is licensed from Triage Technologies Inc. The underlying Triage software is a Health Canada Class I medical device (June 2020) and is CE-marked under the EU Medical Devices Directive (April 2021). 5. **Atrial fibrillation detection.** Smartphone-based AFib detection was first listed as an offering in the FY2024 Appendix 4E. 6. **Health coaching enablement.** Partners can deliver therapeutic and non-therapeutic coaching. This capability came largely from the wellteq acquisition, although the wellteq platform itself was shut in Q4 FY2023. The flagship integrated product is the Biometric Health Assessment (BHA), a multi-step smartphone workflow: - FaceScan plus a demographic and lifestyle questionnaire - Resting heart rate measured by photoplethysmography (PPG) - BodyScan for body composition - A three-minute step test for cardiorespiratory fitness - Algorithmic risk outputs for cholesterol, HbA1c, CRP and similar markers The FY2023 20-F claims the BHA produces 61 health outputs from 41 biometric captures across five categories: cardio-respiratory, body composition, estimated blood biomarkers, metabolic health and mental health. Management presentations in 2024 cited 82 health markers. The difference has not been reconciled publicly. ### Business and revenue model | Revenue mechanism | Description (FY2023 20-F / FY2024 4E) | FY2023 (A$) | FY2024 unaudited (A$) | |---|---|---|---| | SDK – per user | Fee per enrolled user | 35495 | 292 | | SDK – per scan | Fee per completed scan | 2353 | 26387 | | Software subscriptions | Annual/quarterly/monthly licence | 504708 | 107675 | | Integration and development | One-off implementation fees | 107141 | 234075 | | Other revenue (mainly R&D tax incentive and finance-related) | Non-operating | 2140740 | 2313159 | AHI describes itself as a B2B "Digital Health as a Service" (dHaaS) provider with a "one-to-one-to-many" structure. AHI licenses its technology to a partner, and the partner owns the relationship with end users. The 20-F lists four ways partners pay: From 2023, management also moved toward deals priced into the partner's own offering, so AHI is paid regardless of how much end users actually use the technology. One example is the Pharmak Direct digital pharmacy (UAE/Saudi Arabia), where AHI was to earn 1.6% of gross prescription value per Pharmak user (FY2023 20-F risk factors). Large licence-plus-equity structures were also struck. The most notable was the August 2023 China exclusive licence with Changlin Network Technology: a US$10M upfront fee, a US$5M annual fee and a 25% revenue share. No public confirmation has been found that the upfront fee was ever received; an extension was granted in April 2024. **Mix characterisation (analyst view):** Revenue is overwhelmingly software and licensing; there are no hardware or physical products. However, "other revenue" (chiefly the refundable Australian R&D Tax Incentive) made up 77% of FY2023 total revenue and 86% of FY2024 total revenue. AHI's reported top line therefore reflects government R&D rebates more than commercial sales. ### Value-chain position, customers and end markets AHI sits at the technology/IP layer of digital health. It supplies embeddable measurement and risk algorithms to platform owners rather than running consumer apps itself. The exception was the wellteq corporate-wellness platform, which AHI acquired in late 2022 and shut in mid-2023. Customer types and end markets disclosed in the 20-F: - mHealth, telehealth and wellness platforms - Life and health insurers and reinsurers (the Unisure/SCOR letter of intent) - Digital pharmacies (Pharmak Direct) - Employers and corporate wellness (via wellteq, Bearn LLC) - Governments and population-health programmes (Saudi Arabia via IntelliGen; Singapore Healthcare InnoMatch; China via Changlin) - Earlier: fitness and consumer apparel (the BodyScan sizing heritage) **Company's own description, paraphrased (FY2024 Appendix 4E):** AHI aims to become a global leader in digital health by using the ubiquity of smartphones to provide health-screening and triage tools to providers, carers, insurers and governments. Its stated mission is better outcomes, better health literacy and earlier detection of chronic disease. **Independent characterisation:** AHI is a sub-scale, pre-commercial health-AI licensing business. Its proprietary core (BodyScan) is narrow. A significant part of its headline capability (FaceScan, DermaScan) is licensed from third parties on a non-exclusive basis, which limits defensibility. Its go-to-market has depended heavily on announced memoranda, letters of intent and partner launches that have rarely converted into material recurring revenue. In September 2023 it had to retract an announcement that wrongly implied a relationship with AIG.

Revenue$0.0B
Employees19
Market Cap$0.0B
Founded2014
South Perth, Australia
Advance

Advance ZincTek Limited

Premium
Information Technology

Advance ZincTek is a vertically integrated Australian specialty-materials manufacturer. Its core product is high-transparency, pharmaceutical-grade zinc oxide sold under the ZinClear brand, both as powders (ZinClear XP) and as ready-to-formulate dispersions in natural emollients. These are used as broad-spectrum "mineral" UV filters in sunscreens, cosmetics and topical pharmaceuticals. It also makes plate-like alumina effect powders (Alusion, rebranded White Sapphire) for colour cosmetics and is developing magnesium oxide and other cosmetic oxides. It operates from a TGA-licensed, solar-assisted facility in Brisbane and sells mainly through distributors. North America (US and Canada) generated 57% of FY2026 revenue. The investment case rests on the regulatory shift away from organic chemical UV filters (oxybenzone, homosalate, 4-MBC) toward mineral filters. Offsetting this are customer concentration, controlling-shareholder governance, US FDA compliance overhang, very slow inventory turnover, and a newly announced, unproven diversification into home battery storage. --- ### Company's own description (latest Annual Report, FY2026) The FY2026 Directors' Report describes the principal continuing activities as predominantly the manufacture of aluminium oxide powder (Alusion), zinc oxide dispersions and zinc oxide powder, collectively branded ZinClear, for the Personal Care Sector. It reports no significant change in the nature of activities. The operating-segment note (Note 23) identifies one reportable segment, Personal Care. That segment produces and distributes dispersions of mineral-only UV filters in cosmetic emollients for sunscreen, skincare and pharmaceutical formulations, plus alumina plate-like powders for cosmetic applications. The Corporate Governance Statement frames the Board's objective as creating long-term shareholder value through diversified product sales and development in cosmetics and sunscreen. ### Independent characterisation ANO is best understood as a niche active-pharmaceutical-ingredient (API) and cosmetic-ingredient manufacturer. It sits in the upstream-to-midstream part of the personal-care value chain: 1. **Inputs.** It buys raw zinc oxide feedstock and other raw materials from overseas suppliers, sometimes paying deposits in advance (FY2026 AR Note 11: A$172k of supplier deposits). It also buys carrier oils, many of them organic or vegan certified. 2. **Conversion.** It applies proprietary particle-engineering and dispersion know-how, which originated in mechanochemical processing research at the University of Western Australia and was scaled up through a 2000–2004 joint venture with Samsung Corning. The result is transparent, low-whitening zinc oxide powders and high-load dispersions (50% and 65% w/w zinc oxide grades are FDA NDC-listed). 3. **Distribution.** It sells through a network of specialty-chemical distributors in the US/Canada, Europe and Asia. In the US it moved from one exclusive distributor to four non-exclusive distributors during FY2024–FY2025. In Australia it also sells directly to contract sunscreen manufacturers. 4. **Downstream (limited).** It sells finished sunscreen products, mainly to the related party Veganic SKN Limited, and holds capitalised "ZinXation" end-formulation assets. Through a subsidiary established in FY2023, Sunscreen Safety Testing Laboratory Pty Ltd, it offers in-house SPF and safety testing support. ### Business and revenue model | Revenue model element | Assessment | |---|---| | Product vs service vs subscription vs licensing | About 100% product sales recognised at a point in time (AASB 15, FY2026 AR Note 5). No subscription revenue. Licence income was historically recognised (FY2023 accounting policy) but nothing material has been reported since. Testing services via SSTL are not separately disclosed | | Pricing | Not publicly disclosed. Management states it adjusts selling prices for FX movements (no hedging). The FY2023 AR said EcoZinc launched at "increased pricing levels" | | Customer type | B2B: specialty-chemical distributors, contract sunscreen manufacturers, cosmetic brand owners. Related-party B2B: Veganic SKN Limited (sunscreen products, A$1.28m in FY2026) | | Customer concentration | FY2026: three customers at 23.97%, 20.4% and 11.78% of revenue (about 56% combined). FY2025: four customers at more than 11% each, 65% combined. FY2024: three customers, 50% (Note 23(b)) | | End-markets | Sunscreen (OTC drug in US/Australia; cosmetic in EU), daily-wear skincare with SPF, colour cosmetics (alumina effect pigments), topical pharmaceuticals (zinc oxide as skin protectant). Management has identified adjacent agricultural, textile and rubber markets (FY2023 AR) and now home battery storage (FY2026 AR) | | Geographic mix FY2026 | USA & Canada 57.2%; Australia 23.0%; Europe 10.8%; Rest of world 9.0% | ### Value-chain position and moat sources The defensible elements are (i) regulatory licences, namely Australian TGA manufacturing licensing and US FDA drug-establishment registration and NDC listings, which are costly and slow for new entrants to obtain; (ii) particle-dispersion know-how protected partly by patents ("Patented Dispersions" development asset, A$1.2m net book value at FY2026); and (iii) a "clean label" positioning (organic and vegan carrier oils, solar-powered "EcoZinc"). The main weaknesses are scale (about A$13m revenue against multinational competitors), dependence on a few distributors, and the commoditisation risk from lower-priced Asian zinc oxide imports, which management has publicly described as non-compliant in the Australian market (ASX release, 2 Oct 2025).

Revenue$0.0B
Employees25
Market CapN/A
Founded1997
Queensland, Australia
Adslot

Adslot Limited

Premium
Information Technology

Adslot is a micro-capitalisation Australian advertising-technology and digital-marketing group that has spent the past two years contracting from a globally ambitious "automated guaranteed" media-trading platform into a three-unit, 17-person software-and-services business. Its most valuable asset is Symphony, a media-agency workflow-automation platform used by WPP's GroupM (now WPP Media) in a handful of markets under a contract extended in September 2026 for 18 months at a fixed A$3.24 million. Alongside Symphony sit Adslot Media — a marketplace and "StoreFront" self-service ad-sales platform now run on a fee-only model after its operating subsidiary entered voluntary administration and a Deed of Company Arrangement — and Webfirm, a Melbourne SME digital-marketing agency generating roughly A$1.4 million a year. FY2026 revenue was A$5.2 million, underlying (adjusted) net loss A$1.8 million, and cash A$1.6 million. The board's stated objective is to convert a stabilised, simplified group into a "clean listed technology company," with M&A explicitly under consideration. --- ### Company's own description (FY2026 Annual Report) The FY2026 Directors' Report states that Adslot derives revenue from two principal activities. Trading Technology comprises Adslot Media (Marketplace and StoreFront), described as a leading global media trading technology platform, and Symphony, described as market-leading workflow automation technology for media agencies. Services comprises digital marketing services delivered by the Webfirm division and project-based customisation of the Trading Technology platforms. The report's vision statement frames the group's purpose as enhancing client growth through premium digital advertising and marketing technology solutions. The company identifies three sources of revenue: **Software Licence Fees:** primarily from Symphony, in particular from GroupM (WPP). **Digital Services Fees:** primarily from Webfirm, a Melbourne-based digital marketing agency serving SMEs. **Trading Fees:** a percentage of media traded through the Adslot Media platform and StoreFront, including customers such as Rakuten Viber across 41 markets. ### Revenue model mix (FY2026, A$) | Revenue type | Model | FY2026 (A$) | % of revenue for services rendered | |---|---|---|---| | Licence fees | Subscription / fixed-fee SaaS licence (recognised over time) | 2,910,888 | 57.3% | | Trading fees | Transaction-based % of media value (recognised over time) | 721,568 | 14.2% | | Services | Project, retainer and recurring service (SEO/SEM, hosting, web development, custom development) | 1,447,059 | 28.5% | | Total revenue for services rendered | — | 5,079,515 | 100% | Source: FY2026 Annual Report, Note 3. Percentages computed by analyst. The business is therefore, by revenue, primarily a subscription/licensing business (57%), with a services tail (29%) and a shrinking transactional component (14%). There is no product (hardware) revenue. ### Value-chain position Adslot sits in the "direct-sold / guaranteed" layer of the digital advertising value chain — the segment in which a buyer commits in advance to a fixed quantity of premium inventory at a negotiated price, as opposed to real-time-bidding (RTB) programmatic auctions. Symphony sits on the buy side inside media agencies (planning, buying, trafficking and reconciliation workflow). Adslot Media Marketplace historically sat between agencies and publishers as a clearing-house intermediary; StoreFront sits on the sell side as a white-label self-service ad-sales portal for publishers selling to many smaller buyers. Webfirm sits outside ad-tech entirely, as a local agency selling websites, hosting, SEO and paid-search management to SMEs. ### Customer types and end-markets | Customer type | Products | Named customers (disclosed) | |---|---|---| | Global media agency holding companies | Symphony | GroupM / WPP Media (China, Australia, Malaysia, Austria, South Africa under Sep 2026 extension); Together NZ (segment note) | | Digital publishers / media owners | StoreFront, Marketplace | Rakuten Viber (41 markets), Vox Media (US), Hearst (UK), Bloomberg, ResearchGate (StoreFront clients signed H1 FY2025) | | Property portal (former) | Adslot technology licence | REA Group (terminated Dec 2025 after ~15 years) | | Advertisers / SMEs | StoreFront (as buyers), Webfirm services | Not individually disclosed | | Channel partners | Marketplace / reseller | Goldvertise (Germany CTV — discontinued in FY2026); Infomo Global (Singapore/India reseller) | Two customers each accounted for ≥10% of FY2026 revenue (one in FY2025) (FY2026 Annual Report, Note 2(b)); the company does not name them, but the GroupM contract value and segment disclosures make GroupM almost certainly one of them. ### Independent characterisation Adslot today is best understood as a sub-scale, customer-concentrated legacy software asset (Symphony) cross-subsidising two sub-scale growth or lifestyle businesses (Adslot Media and Webfirm). Symphony generated A$0.96 million of segment EBITDA on A$2.67 million of revenue in FY2026 — the only meaningful profit pool — while Adslot Media lost A$0.49 million at segment level and Webfirm broke even. Group-level corporate costs of A$2.23 million consumed all segment profit. The decade-long thesis that Adslot would become the global standard for automated guaranteed trading did not materialise: trading-fee revenue has declined every year since FY2022 (A$1.23m → A$0.72m), and the clearing-house model was abandoned through the administration of Adslot Technologies Pty Ltd in June 2026. The investment case is now essentially one of (i) contracted Symphony cash flows, (ii) a materially de-risked balance sheet, (iii) the residual option value of StoreFront, and (iv) the listed shell's value in a potential merger or reverse transaction.

RevenueN/A
Employees17
Market CapN/A
Founded1975
Sydney, Australia
Admiralty

Admiralty Resources NL

Premium
Information Technology

Admiralty Resources NL is a long-listed Australian junior that has turned itself into an emerging iron ore concentrate producer focused on Chile. Its flagship asset, the Mariposa magnetite iron ore project, lies about 10 km south of Vallenar in the Atacama Region, inside Chile's coastal iron belt. Mariposa carries a JORC 2012 Mineral Resource of 105.6 Mt and an Ore Reserve of 36.3 Mt, which together support roughly 14 Mt of ~65% Fe concentrate. Since June 2024 the company has used a capital-light model. Under a Joint Operating Agreement, Chinese partner Hainan Xinlei Mining Management funds and operates the project, and Admiralty keeps a 20% share of notional net profit after tax. Product is marketed through Trafigura on index-linked terms, and concentrate is also sold domestically to CMP. Satellite tenements at Soberana, La Chulula, Pampa Tololo and El Cojin add optionality, alongside a dormant 50% stake in the Pyke Hill nickel-cobalt project in Western Australia. Against these positives sit a negative equity position, a going-concern material uncertainty and an ASX suspension. --- ### Company's own description In its FY2025 Annual Report and quarterly reports, Admiralty describes itself as a public diversified mineral exploration company listed on the ASX, with mineral interests in Chile and Australia. It says it is advancing production at its flagship Mariposa Iron Ore Project in Chile, which entered pre-production in 2024 and was ramping up output in 2025. The Directors' Report states that the group's principal activity during FY2025 was "mineral exploration". ### Independent characterisation In economic substance, Admiralty is now a royalty-like project owner rather than a mining operator. Under the Joint Operating Agreement executed on 25 June 2024 (FY2025 AR, Note 5): - Hainan Xinlei Mining Management Co Ltd ("Hainan") supplies all capital equipment and carries out all development needed to reach Phase 1 production of 500,000 t/pa, then progresses towards a 2,000,000 t/pa plant. - Hainan bears all project liabilities, costs and expenses up to the point of sale of product. - Admiralty retains 20% of the project's notional net profit after tax. - An Operating Committee of one Admiralty representative and two Hainan representatives decides matters by majority. Management therefore concluded that Admiralty does not have joint control under AASB 11, so the arrangement is not accounted for as a joint operation or joint venture. Admiralty holds the Chilean mining concessions through Admiralty Minerals Chile Pty Ltd Agencia en Chile. It also acts as the administrative conduit for the project: sale proceeds and Chilean VAT refunds pass through its bank accounts on Hainan's behalf. These flows are presented net and matched by a payable to Hainan (FY2025 AR, Notes 12 and 17). ### Revenue model | Revenue model element | Status (FY2025 AR / FY2026 quarterlies) | |---|---| | Product sales (iron ore concentrate) | Economically attributable to Hainan until profits are shared. ADY recognised no sales revenue in FY2025. | | Profit share (20% of notional NPAT) | ADY's core future economic interest. No profit-share income has been reported to date. | | Services / subscription / licensing | None | | Other income | Interest, FX gains and fair-value movements (A$211,971 in FY2025) | ### Value chain position, customers and end-markets **Value chain:** Upstream mining and beneficiation of magnetite into ~65–66% Fe concentrate. Product is trucked to Las Losas port (Huasco) and, since the June 2026 approval, also to Guacolda II. It is exported seaborne or sold domestically. **Customers / offtakers:** - Trafigura Pte Ltd, the international marketer under an open-book purchase contract (announced 28 November 2025), with pricing referenced to the Metal Bulletin 65% Fe CFR North China index. - Compañía Minera del Pacífico (CMP), under a purchase order for at least 10,000 t/month of 65% Fe concentrate delivered to Guacolda 2 from March 2026 (December 2025 Quarterly, per InvestorPA summary). **End-markets:** Chinese steelmakers. The second overseas shipment, MV IDAWN FZ, departed on 1 April 2026 "bound for customers in China" (FY2025 AR, Note 25). The product sits in the high-grade (65% Fe) segment that serves blast-furnace blending and, potentially, lower-emission steelmaking routes.

RevenueN/A
Employees3
Market CapN/A
Founded1981
North Sydney, Australia
Adhesive

Adhesive Applications Ltd.

Premium
Information Technology

Adhesive Applications, Inc. is a small, family-owned US manufacturer of pressure-sensitive adhesive (PSA) tapes. It is based in Easthampton, Massachusetts, and traces its roots to 1970. Its core business is precision coating of silicone, acrylic, rubber and hot-melt/heat-activated adhesives onto polyethylene foam, polyester and polyimide film, tissue, scrim, paper, cloth, foil and customer-supplied carriers. The output is converted into foam tapes, film tapes, transfer adhesives and fully custom constructions. The company sells mainly to industrial converters, die-cutters, gasket fabricators and OEM engineering teams in medical devices and diagnostics, automotive, building and construction (windows and fenestration), aerospace, electronics, appliances, graphics and, more recently, data-center infrastructure. Global majors compete on scale. Adhesive Applications instead competes on application engineering, fast sampling, low-volume flexibility and chemistry breadth, especially specialty silicones. Its stated growth bets are a 2023–2026 solvent-free UV hot-melt coating line and medical, microfluidics, EV battery and aerospace applications. In April 2026 it appointed a new General Manager. --- ### Company's own description In its own materials the company calls itself an innovative manufacturer and developer of PSA tapes. It says it offers a complete line of silicone, rubber, acrylic and hot-melt adhesive technologies, combined with foam, film, woven, non-woven, custom and customer-supplied carriers (About page, 2025). Its directory listings describe it as a single-source supplier for bonding, laminating, mounting, gasketing, splicing and sealing, with an on-site technical staff and lab that develop application-specific products (QMed / GlobalSpec directory text). The homepage positions it as a leading adhesive-tape coater serving medical, industrial, aerospace and electronics applications. The company does not publish an annual report, so these website descriptions stand in for the "latest annual report" description. ### Independent characterisation Adhesive Applications is a mid-stream specialty coater and converter in the PSA tape value chain. Upstream, it buys adhesive polymers (acrylic, rubber/elastomer, silicone systems), carrier substrates (PE foam, PET and polyimide film, tissue, foil) and release liners (paper, PE-coated paper, PET, polyolefin). It adds value through formulation and compounding know-how, coating (solvent-borne, water-borne, 100%-solids hot melt with UV cure), lamination, slitting and spooling, and quality testing. Downstream, most output goes to converters and fabricators, including die-cutters, gasket fabricators and medical-device component makers. These customers turn rolls into finished parts for OEMs. Customer testimonials on the website confirm this channel profile: - Fralock, a precision converter, says the relationship spans two decades. - Stockwell Elastomerics, an elastomer fabricator, credits the company with a silicone solution developed for a rapid COVID-19 response. - The Tape Lab, a tape distributor and converter, praises its specialty silicones. - Neodyne Biosciences, a medical device maker, says it has used custom stick-to-skin adhesives for more than 10 years. - Zotefoams, a foam producer, describes a multi-industry partnership. ### Business and revenue model | Dimension | Assessment | Basis | |---|---|---| | Product vs. service mix | Predominantly product sales (coated rolls, slit rolls, spools). Development and testing are bundled into the sale rather than billed separately as far as disclosed | Capabilities page; product catalog | | Custom vs. standard | Hybrid. A catalog of about 242 standard SKUs alongside custom coating, including coating of customer-supplied substrates | Product catalog filters; Capabilities page | | Subscription / licensing | None disclosed | — | | Pricing model | Quote-based (website "Get a Quote" workflow); no list prices published | Website | | Order formats | Log rolls up to 61.5 in wide × up to 2,100 ft; slit rolls 3/16 in to 61.5 in wide, up to 1,500 ft (common lengths 72, 36, 18 yd); continuous spools 3/16 in to 1 in wide, up to 15,000 ft | Capabilities page | | Revenue split by product/segment | Not publicly disclosed | — | ### Customer types and end-markets | End-market (company-defined) | Catalog SKUs tagged (website filter, Oct 2026) | Typical applications (company and directory descriptions) | |---|---|---| | Building / Construction | 56 | Window and fenestration glazing and mounting (AAMA-certified products), sealing, mounting | | Automotive | 32 | Mounting, gasketing, foam bonding; EV battery cited as a target in the 2022 grant release | | Appliances | 27 | Gasketing, bonding, mounting | | Graphics | 27 | Sign and display mounting (historic sign-industry coverage in SignShop) | | Electronics | 18 | Film and silicone tapes; microelectronics targeted | | Medical | 17 | Skin-contact tapes, wearables, microfluidics and diagnostic devices; ISO 10993 tested | | Aerospace | 15 | Lightweight bonding and silicone tapes | | Data Centers | Not tagged in catalog filter | Industry page added to website navigation (date not disclosed) | | HVAC, solar, retail | Not in current navigation | Listed in Bloomberg profile description | The SKU counts measure catalog breadth, not revenue. Products can carry several industry tags.

RevenueN/A
Employees72
Market CapN/A
Founded1970
MA, US
ADEKA

ADEKA Corporation

Premium
Information Technology

ADEKA is a century-old Japanese specialty chemicals and food-ingredients group that has moved from chlor-alkali and hydrogenated oils into three profit pools: Chemicals, Food Products and Life Science. Chemicals covers polymer additives, semiconductor materials and "environmental materials". Life Science is the 51%-owned agrochemical maker Nihon Nohyaku. Net sales reached a record JPY 416.6 billion in FY2025 with a 10.0% operating margin, and 54% of sales came from outside Japan. The strategic centre of gravity is advanced semiconductor materials: high-k ALD precursors for leading-edge DRAM, photoacid generators and metal compounds for EUV resists. Trade press credits ADEKA with the top global share in ALD materials for advanced memory. Polymer additives provide global scale through plants in the US, France, UAE, China, Korea and Thailand, while agrochemicals and processed fats supply steadier cash flow. Under the ADX 2026 plan, management is shifting from scale to return on capital, backed by a net-cash balance sheet, a 40%+ payout policy and its first market buyback. --- **What the company does.** ADEKA develops, makes and sells functional chemicals and processed food ingredients, and through Nihon Nohyaku it discovers, makes and sells crop-protection products. Its reportable segments are the Chemicals Business, the Food Products Business and the Life Science Business. A small "Others" category holds plant engineering and construction, logistics, warehousing, vehicle leasing, real estate and insurance agency services (T-FY25, segment note). **The company's own description (paraphrased from the FY2025 Business Report, AGM164).** The group describes itself as a provider of valuable materials ("SOZAI") that can transform industry and society. Its management policy has two limbs: staying progressive and dynamic in the face of change, and creating a better future for people worldwide. Its 2030 vision reads "An Innovative Company Contributing to a Sustainable Future and Affluent Lifestyles" (AGM164). The Business Report lists the principal businesses as follows. **Independent characterization.** ADEKA is best read as a three-engine holding of B2B formulators. 1. *Polymer additives* (24% of FY2025 sales) is a global, mid-margin franchise at about a 10% operating margin. It sells antioxidants, light stabilizers, nucleating and clarifying agents, PVC stabilizers and intumescent flame retardants to resin producers and compounders. It is volume- and price-sensitive and exposed to Chinese and Korean competition. 2. *Semiconductor materials* (9% of sales) earns 20–27% operating margins. Its products are consumable precursors and resist ingredients qualified into specific device nodes at a small number of memory and logic makers and resist formulators. 3. *Environmental materials* (19% of sales) is a broad specialty portfolio: molybdenum-type lubricant additives, reactive emulsifiers, specialty epoxies, display photo-curing materials, surfactants, propylene glycol and peroxides. 4. *Life Science* (27% of sales) is the listed 51% subsidiary Nihon Nohyaku. It is seasonal, with a fourth-quarter peak, and exposed to Brazil and India. 5. *Food Products* (20% of sales) is a domestic-leaning processed fats business with China and Southeast Asia operations, earning about 5% margins. **Business model and revenue model.** Revenue is almost entirely product sales to industrial customers. The disclosures reviewed show no subscription revenue and no material licensing revenue. Service revenue is confined to "Others" (JPY 6.95 billion, 1.7% of FY2025 sales). Nihon Nohyaku also earns some technical licensing and contract-manufacturing income, which is not separately disclosed in the ADEKA tanshin. **Value-chain position.** ADEKA sits mid-stream. It buys naphtha-derived intermediates, vegetable oils (notably palm), metals and specialty reagents, then synthesizes and formulates performance ingredients. Its customers are resin makers, compounders, semiconductor device makers, photoresist makers, lubricant blenders, paint and adhesive makers, bakeries and confectioners, and (via Nihon Nohyaku) agricultural distributors and cooperatives. Management notes that some products depend on naphtha-derived raw materials and that Middle East tensions have tightened supply of certain inputs (T-FY25). **Customer types and end-markets (BR-FY25, slide 3-6).**

Revenue$2.8B
Employees5,434
Market Cap$2.8B
Founded1917
Tokyo, Japan
AdAlta

AdAlta Limited

Premium
Information Technology

AdAlta is a virtual, clinical-stage Australian biotechnology company that has transformed itself from a single-platform protein-therapeutics discoverer into an "East to West" cell-therapy developer. Its business model is to in-license clinically validated, highly differentiated T-cell therapies for solid cancers from Asian (predominantly Chinese) originators, re-establish their manufacturing in Australia to US FDA standards, run first Western Phase 1 studies under an FDA IND, and then on-license each product to larger biopharmaceutical companies, sharing proceeds with the originator. Its first asset, EW-001 (formerly BZDS1901), is a PD-1-armoured mesothelin CAR-T licensed from Shanghai Cell Therapy Group for all markets outside Greater China, with an FDA pre-IND meeting scheduled for 4 November 2026 (AEST). Legacy i-body assets—Phase 2-ready anti-fibrotic AD-214 and anti-malarial WD-34—are held for partnering. The company is cash-constrained, carries a going-concern qualification and trades as a deep-penny stock. --- ### Company's own description (FY2026 Annual Report) The FY2026 Annual Report describes AdAlta as a clinical-stage biotechnology business whose principal activity is developing next-generation cellular immunotherapies for solid cancers, together with commercialising protein therapeutics previously discovered on its proprietary i-body® platform. Through the "East to West" strategy, the company states that it integrates Asia's capability in T-cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem, in-licensing clinically de-risked products from Asian originators, investing to establish FDA-regulated manufacturing and early clinical studies, and positioning each product for on-licensing to larger biopharmaceutical companies for registrational studies and commercialisation. Management describes the model as deliberately capital efficient, designed to return investment on each project within three to four years, and replicable across multiple products. ### Independent characterisation In substance, AdAlta is a development-stage asset aggregator and regulatory/manufacturing "translator" rather than a discovery company. Its value-add sits in the middle of the pharmaceutical value chain: **Upstream (sourcing):** screening Asian cell-therapy assets that already have human clinical data in solid tumours. AdAlta uses an in-house AI screening agent ("EMU", built on Anthropic's Claude) to produce referenced preliminary due diligence and score candidates against its selection criteria. **Midstream (value creation):** technology transfer of manufacturing to an Australian contract manufacturer (Cell Therapies Pty Ltd, Melbourne), FDA pre-IND engagement (with Dark Horse Consulting Group as regulatory adviser), and first-in-Western-patient Phase 1 studies in Australia, exploiting Australia's comparatively fast and cost-efficient clinical-trial environment and R&D Tax Incentive. **Downstream (monetisation):** out-licensing or sale of each asset after Phase 1, with AdAlta entitled to 60% of the proceeds of any commercialisation event following Phase 1 completion for EW-001 (FY2026 Annual Report). The legacy i-body portfolio (AD-214, WD-34) is now a non-core monetisation pool: management is pursuing out-licensing, spin-out, or grant-funded paths and has ceased internal discovery R&D (February 2025). ### Revenue model | Revenue type | Current status (FY2026) | Commentary | |---|---|---| | Product sales | Nil | No approved products | | Services / collaboration revenue | Nil in FY2025–FY2026 | Historical collaboration income (GE Healthcare, Carina Biotech) appears to have ceased | | Licensing (out-licensing upfronts/milestones/royalties) | Nil to date | Target monetisation route for AD-214, WD-34 and, post-Phase 1, EW-001 | | Government grants / tax incentives | A$404,245 R&D Tax Incentive (RDTI) recognised as "other revenue" in FY2026 (FY2025: A$677,010) | The sole recurring inflow; at risk from proposed RDTI changes in the 12 May 2026 federal budget | | Interest income | A$73,987 (FY2026) | Immaterial | ### Customer types and end-markets There are no customers in a commercial sense. Prospective counterparties are (i) large and mid-sized biopharmaceutical companies seeking Western-validated solid-tumour cell therapies (the eventual licensees of EW-001 and successor assets); (ii) fibrosis-focused pharma (IPF, interstitial lung disease, kidney fibrosis) for AD-214; and (iii) global-health funders, defence/travel-medicine stakeholders and vaccine developers for WD-34. End-markets: oncology (mesothelioma and other mesothelin-expressing cancers such as ovarian, pancreatic and some lung cancers), fibrotic disease, and infectious disease (malaria, babesiosis, toxoplasmosis).

RevenueN/A
Employees2
Market CapN/A
Founded2006
Hawthorn East, Australia
Adairs

Adairs Limited

Premium
Information Technology

Adairs Limited is a vertically integrated, design-led home furnishings group operating three wholly owned brands in Australia and New Zealand: **Adairs:** specialty bed linen, bedding, bath, homewares, kids and furniture; 160 stores and online. **Mocka:** online-led, design-led home and living furniture and décor, now trialling standalone stores. **Focus on Furniture:** value-to-mid-market lounge, dining and bedding showrooms; 27 stores. In FY26 the group generated A$641.7m of sales, A$55.0m of underlying EBIT and a statutory loss of A$39.4m after a A$63.5m impairment of Focus on Furniture. Its competitive moat is the paid Linen Lovers loyalty programme: about 1 million members contributing more than 80% of Adairs brand sales. This is supported by exclusive in-house product and an omnichannel model in which online is 32.6% of sales. The investment case is a three-speed portfolio: - Adairs is recovering margins. - Mocka is scaling rapidly at a 14% EBIT margin. - Focus is in a two-year turnaround. This now sits alongside a second CEO transition in two years and a share price that has more than halved in twelve months. --- **Company's own description (2026 Annual Report, paraphrased).** Adairs Limited operates leading omnichannel specialty retailers in Australia and New Zealand through three distinct businesses: Adairs, Mocka and Focus on Furniture. Each business: - is design-led; - sources and procures its own products; - retails through owned or controlled channels; and - operates as a wholly owned subsidiary that functions independently in all material respects. The group coordinates governance, treasury, leasing, supply chain, people, and risk/sustainability centrally. The FY26 presentation summarises the portfolio as three brands at three different stages: - Adairs growing profitably; - Mocka scaling fast; - Focus on Furniture in turnaround. **Business model.** Adairs is a vertically integrated specialty retailer. Product is designed in-house (Melbourne for Adairs and Focus, Brisbane for Mocka), manufactured by third-party factories, imported, and sold exclusively through company-controlled stores and websites. There is no wholesale, licensing or marketplace revenue of significance. Revenue is close to 100% product sales. The one quasi-subscription element is the paid Linen Lovers membership. Its fee revenue is not separately disclosed, and part of it is held in deferred revenue (A$20.8m at June 2026, all categories). The FY26 presentation also cites delivery and finance options: - Focus offers finance through Latitude Finance (1H FY26 presentation). - Mocka offers click-and-collect from its Brisbane and Christchurch DCs. **Revenue mix (FY26, FY26 Results Presentation)** **Value-chain position.** Adairs captures the design, brand and retail margin: - Group gross margin before warehouse and delivery costs is 59.0%; after those costs it is 47.1% (FY26). - It outsources manufacturing; 73% of group stock purchases by value are from China/Hong Kong (2026 Annual Report). - The Adairs brand runs its own National Distribution Centre (NDC) in Truganina/Melbourne. Operational control was brought in-house from a 3PL in August 2023, and the NDC assets were acquired for A$12.5m in FY24. **Customer types and end-markets.** The business is overwhelmingly B2C retail to Australian (and, for Mocka, New Zealand) households, skewed to female, mid-market, home-proud consumers. End-markets are: - Home textiles and furnishings: bed linen, bedding, towels, cushions, throws, rugs, décor, fragrance, gifting, kids. - Small-format and occasional furniture: Adairs and Mocka. - Bulky furniture and bedding: Focus (lounge, dining, bedroom, mattresses). - Nursery and kids furniture: Mocka and Adairs Kids. **Independent characterisation.** Adairs is best understood as a loyalty-led specialty textiles retailer with two furniture adjacencies bolted on through acquisition. **The core Adairs franchise:** produces about 75% of group underlying EBIT. Its economics rest on a paid membership that drives repeat visits to "Big Moments" promotional events. Its historic weakness has been promotional dependency: EBIT margin compressed from 13.3% in FY22 to 7.7% in FY24 before recovering to 9.0% in FY26. **Mocka:** has become a high-quality, capital-light growth engine: 14.1% EBIT margin, A$71m sales, +38% in Australia. **Focus on Furniture:** has been the principal value destroyer since FY24. EBIT fell from A$27.4m (FY23) to A$3.8m (FY26) and goodwill has been written to nil.

RevenueN/A
Employees1,969
Market CapN/A
Founded1918
Victoria, Australia
Acumentis

Acumentis Group Limited

Premium
Information Technology

Acumentis Group Limited is Australia's only independent, locally owned, ASX-listed property valuation company, providing residential, commercial, rural/agribusiness, government, insurance and business valuations, together with an expanding suite of property advisory services (tax depreciation, quantity surveying, capital gains tax valuations, ESG advisory, plant and equipment/asset advisory). It operates a national network of roughly 40 metropolitan and regional offices with more than 300 staff and generated AUD 56.7M of service revenue in FY2026. Historically dependent on bank mortgage-valuation panels, the group has spent the five years since its 2019 cyber-breach crisis rebuilding panel access and diversifying: non-mortgage services exceeded 47% of revenue in FY2026. Earnings quality is improving — FY2026 profit before tax rose 43.9% despite a 2.5% revenue decline — and the balance sheet carries no bank debt and AUD 7.1M of cash. The near-term investment case hinges on a proprietary, AI-enabled job management platform, governance stability after a failed 2026 board spill, and a second-strike risk at the 2026 AGM. --- ### What the company does Acumentis sells professional opinion — independent valuations of real property and businesses, and related advisory work — billed on a per-engagement fee basis. The company's own principal-activity statement in the FY2026 directors' report describes the business as property valuation and advisory services and notes there was no significant change in the nature of activities during the year. Its standard ASX boilerplate describes it as being trusted to provide commercial and residential valuations, research and property advice to homeowners, investors, developers and lenders, serving major banks and financial institutions, developers, property trusts, government, lawyers, accountants, real estate agents and retailers. The FY2026 Annual Review describes the strategy in terms of being a "one-stop shop": by expanding into service lines with strong demand — ESG, quantity surveying and capital gains tax (CGT) valuations — the company aims to reduce dependence on any single revenue stream such as mortgage-security valuations. Management states that non-mortgage-related services now account for more than 47% of total revenue (FY2026 Annual Report, p.7). ### Business model and revenue model | Revenue model element | Description | FY2026 evidence | |---|---|---| | Service fees (dominant) | Fee per valuation/advisory engagement; recognised at completion of the single performance obligation (report delivery) | Revenue from rendering services AUD 56.43M (FY2026 AR, Note 1) | | Recovery of disbursements | Pass-through of costs (searches, travel) where contracts permit | AUD 0.22M (FY2026) vs AUD 0.06M (FY2025) | | Shared-services recharge to licensees | Monthly recharge to licensed (non-controlled) offices | AUD 0.02M (both years) | | Licence fees (other income) | Percentage-of-revenue fee from non-controlled licensees using the Acumentis brand and systems | AUD 0.108M (FY2026) vs AUD 0.103M (FY2025) | | Equity-accounted income | Share of profit from 37.5% associate Valuations Pty Ltd (Mandurah, WA) | AUD 0.045M (FY2026, first year) | | Product / subscription / licensing of IP | None material today. Management flags future income streams from data and models developed with agtech partner Agtuary | FY2026 Directors' Report, Outlook | The mix is effectively ~100% professional services, with negligible licensing income. There is no subscription or product revenue at present. ### Value-chain position Acumentis sits at the independent-opinion node of the Australian property transaction chain. For mortgage work it is typically engaged via lender valuation panels — often through valuation-management platforms — and paid per job; its economic position is that of a panel supplier competing on turnaround, quality, coverage and price. For non-finance work (government acquisitions, family law, SMSF, probate, tax depreciation, insurance, compulsory acquisition, litigation/expert witness), it is engaged directly by the end client or their advisers, where pricing power and margins are generally better and demand is less correlated with lending volumes. ### Customer types and end-markets | Client category (gross trade receivables, AUD M) | FY2025 | FY2026 | |---|---|---| | Financial clients | 4.03 | 2.95 | | Non-financial clients | 0.94 | 1.69 | | Government non-financial clients | 1.00 | 0.34 | | Total | 5.96 | 4.98 | Trade-receivable disclosures (FY2026 AR, Note 11) give the best available proxy for customer mix: The largest single financial client's receivable fell from AUD 0.83M to AUD 0.37M, consistent with the impairment-test disclosure that a financial client contract was lost during FY2026. End-markets served: residential mortgage lending; commercial property investment and lending; rural and agribusiness; government (infrastructure acquisitions, rating/land valuation, public housing); legal and family-law matters; SMSF and accounting-driven valuations; tax depreciation and quantity surveying for investors; insurance replacement valuations; business valuations. ### Independent characterisation Acumentis is a labour-intensive, mature, cyclical professional-services firm. Employee expenses absorbed 73.9% of service revenue in FY2026 (74.4% in FY2025, analyst-derived), leaving limited operating leverage absent productivity gains. Its strategic logic is sound but incremental: shift mix toward non-finance work, which is less price-competitive and less exposed to lender panel allocation decisions, and use technology to lift valuer productivity. Its distinguishing assets are national regional coverage (especially Queensland, NSW, NT, WA and Tasmania rural capability inherited from Taylor Byrne and later bolt-ons) and its independence from global brokerage groups. Its key weaknesses are scale (sub-AUD 60M revenue), dependence on a handful of lenders and government agencies, and a governance environment that has become contested in 2025–26.

RevenueN/A
Employees300
Market CapN/A
Founded2026
South Brisbane, Australia
ActivEX

ActivEX Limited

Premium
Information Technology

ActivEX Limited is a Sydney-headquartered, ASX-listed junior mineral explorer with about twenty years of history in Queensland copper-gold exploration. Over 2024–2026 it has reshaped itself from a broad, debt-funded copper-gold tenement holder into a lean "gold and critical minerals" explorer. Its most valuable asset is now a 24.5% equity-accounted interest in Gilberton Gold Pty Ltd. This joint venture, controlled by HK Create Capital Investment Group, holds the Mt Hogan deposit in north Queensland, which carries a maiden JORC Mineral Resource of 8.5Mt at 1.13 g/t Au for about 310,000 oz. Directly, ActivEX holds the Georgetown gold/critical-metals tenements and two early-stage rare earth element (REE) plays: Aramac (granted) and Westgrove (applications). The non-core Esk copper-gold project, which included the Coalstoun and Barambah resources, was transferred to its lender to retire all debt in March 2026, and the Pentland interest was sold. The company is now debt-free but cash-thin. It depends heavily on Asian-domiciled placees and on its related corporate group, ASF Group. --- **Company's own description.** The latest half-year report (December 2025) describes ActivEX as being "at the forefront of mineral exploration," focused on finding high-value mineral resources, with an emphasis on sustainability and innovation and on delivering lasting shareholder value and community benefit. Earlier filings (2021–2022) used a more traditional formula: a company committed to acquiring, identifying and delineating new resource projects through active exploration, with a portfolio focused on copper and gold in north and southeast Queensland. By the December 2022 half-year report, the stated focus had broadened to "gold, lithium, and base metals." By 2025–2026 it had shifted to gold, rare earths and critical metals. **What the company actually does.** ActivEX acquires exploration permits for minerals (EPMs) in Queensland and then does three things with them: 1. Generates targets through desktop compilation of historical and open-file geophysical data. 2. Runs low-cost field programs: mapping, soil and rock-chip sampling, portable XRF, and occasionally reverse-circulation (RC) drilling. 3. Monetises the ground through farm-outs, joint ventures or outright sales once exploration has added value. The going-concern note in the December 2025 accounts states the model directly. Exploration has historically been financed by equity and joint operations, and funding options include share issues, borrowings, farm-outs and "the sale of exploration assets where increased value has been created through previous exploration activity." **Revenue model.** ActivEX has no operating revenue. It is a pre-development explorer. "Other income" is trivial: tenement deposit refunds of A$1,088 in H1 FY2026 and A$5,233 in H1 FY2025, plus small government subsidies in earlier years. Economic value is realised through: **Asset sales and farm-outs:** - Cloncurry sold to Fetch Metals (2022) for $3m of mixed consideration. - Ravenswood 49% sold to Ballymore Resources (2021) for 2m BMR shares. - Gilberton 75.5% sold to HKCCIG (2024–25) for $1m cash plus $1m invested into the JV. - Pentland 49% sold (2025) for $49k. - Esk transferred to Star Diamond (2026) to extinguish about $2.3m of debt. **Optionality:** retained JV equity (24.5% of Gilberton Gold Pty Ltd). On the template's product / service / subscription / licensing classification, the mix is 0% across all categories. Value is realised through asset monetisation, which is booked as disposal gains or losses and investment proceeds, not as revenue. **Value-chain position.** ActivEX sits at the very front of the mining value chain: grassroots-to-advanced exploration. It does not mine, process or sell metal. The nearest it has come to development thinking is a 2021–22 review of a third-party 250ktpa gold plant near Georgetown (Kempton Minerals, on care and maintenance) as a possible toll-treatment option for Gilberton. **Customer types and end-markets.** ActivEX has no customers in the commercial sense. Its "buyers" are: - larger explorers and miners seeking projects (e.g., Ballymore Resources, Fetch Metals, Pentland Minerals Pty Ltd); - strategic financiers and JV partners (HK Create Capital Investment Group); - equity investors. The ultimate end-markets of its target commodities are gold (investment and jewellery demand), and REEs and critical metals (permanent magnets for EVs and wind, defence, electronics). Historically they also included copper (electrification). **Independent characterisation.** ActivEX is best understood as a related-party-anchored, capital-light "project incubator" that has spent most of the past decade on a capital-preservation footing. Its defining features are: - a long-tenured board, with the Chair in place since 2012–13; - a part-time-scale operating cost base, with the Managing Director's total remuneration at about A$80k in FY2025; - a historic dependence on a single lender (Star Diamond Developments, 12% p.a.) and on a related corporate-services provider (ASF Group); - a recent strategy of trading 100% project ownership for funding certainty. The March 2026 debt-for-asset swap removed the solvency overhang. It also removed the company's two directly held JORC resources (Coalstoun copper and Barambah gold-silver). As a result, ActivEX's resource exposure is now indirect, through a 24.5% minority stake in a JV it does not control.

RevenueN/A
Employees1
Market CapN/A
Founded2005
Sydney, Australia
Actinogen

Actinogen Medical Limited

Premium
Information Technology

Actinogen Medical is a Sydney-based, ASX-listed, clinical-stage biotechnology company with a single platform asset, Xanamem (emestedastat), a brain-penetrant, once-daily oral inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which regenerates active cortisol inside brain cells. The company's thesis is that chronically elevated brain cortisol damages neurons and contributes to cognitive decline and mood disorders, and that lowering it intracellularly can slow Alzheimer's disease (AD) progression and treat depressive symptoms. Its pivotal Phase 2b/3 XanaMIA trial (247 participants with biomarker-confirmed progressive mild-to-moderate AD, 10 mg vs placebo over 36 weeks) completed its last patient visit on 22 September 2026, with topline results guided for November 2026. Actinogen positions Xanamem as a convenient oral alternative or complement to infusion-based anti-amyloid antibodies, avoiding the MRI-monitoring burden associated with ARIA. Pre-revenue, it funds itself through equity raisings and Australia's refundable R&D Tax Incentive. --- ### What the company does Actinogen is a drug developer, not a commercial-stage pharmaceutical company. Its entire enterprise value rests on Xanamem. The company in-licensed/acquired the molecule (originally discovered at the University of Edinburgh, coded UE2343) through its acquisition of Corticrine Limited in the mid-2010s, then reshaped itself from an earlier natural-products (actinomycete-derived antibiotic) discovery business into a neuroscience company. The company's own description (repeated in ASX announcements and the FY2025/FY2026 annual report boilerplate) is that it is developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol, targeting the substantial unmet need in cognitive dysfunction and behavioural abnormalities. In 2026 communications it describes itself as being in the late clinical stages of developing Xanamem for Alzheimer's disease and depression. ### Business model **Development model:** Virtual/outsourced. Clinical trials are run through contract research organisations (CROs) and investigator sites in Australia and the United States; drug substance and tablet manufacture are outsourced (commercial-grade 10 mg tablets produced at Catalent's US facility; a 15 kg drug-substance batch has been manufactured). **Monetisation pathway (stated):** If XanaMIA is positive, management intends to pursue regulatory engagement on accelerated pathways (including with the US FDA), run a second, larger multinational pivotal trial (planned for 2027), and, per sponsored research commentary, seek a potentially transformative licensing/partnering deal. A Chief Commercial Officer was appointed in FY2025 and market research is under way. **Revenue model mix:** Product 0%, service 0%, subscription 0%, licensing 0%. Reported "revenue and other income" is overwhelmingly the refundable Australian R&D Tax Incentive (e.g. A$12.67m of A$13.17m total income in FY2026), plus interest. ### Value-chain position Actinogen sits at the discovery/clinical-development end of the pharmaceutical value chain, owning IP and clinical data. It has no sales force, distribution or manufacturing plants. Value capture would come via (a) out-licensing to a large pharma with commercial infrastructure in neurology, (b) a co-development deal, or (c) acquisition. ### Customer types and end-markets (prospective) **Ultimate patients:** People aged 50+ with mild-to-moderate AD and biomarker-confirmed progressive disease (elevated plasma pTau181); patients with major depressive disorder (MDD) with cognitive impairment; historically fragile X syndrome was explored. **Prescribers:** Neurologists, geriatricians, psychiatrists, and potentially primary care (an oral pill without MRI monitoring is a key differentiator versus infusion antibodies). **Payers:** US Medicare/commercial payers, European national health systems, Australian PBS. **Near-term "customers":** Potential pharma licensees. ### Independent characterisation Actinogen is a high-risk, binary, single-asset micro/small-cap biotech whose risk profile has been partially reduced by (i) three positive independent Data Monitoring Committee (DMC) reviews, including a January 2026 interim efficacy non-futility review, (ii) over-enrolment of XanaMIA (247 vs original target), (iii) regulatory alignment with FDA (September 2025 Type C meeting) and EMA (scientific advice, May 2026), and (iv) a funded runway beyond the readout into mid-2027. However, the mechanism has historical failures: the company's own XanADu Phase 2 trial (2019) missed its primary endpoints, and an earlier 11β-HSD1 inhibitor from a large pharma did not show efficacy in AD. The current trial's enrichment strategy (pTau181-elevated patients) is based on post-hoc analysis of XanADu, which is a recognised source of risk.

RevenueN/A
Employees6
Market CapN/A
Founded1999
Sydney, Australia
Acrux

Acrux Limited

Premium
Information Technology

Acrux Limited is a Melbourne-based micro-capitalisation specialty pharmaceutical company with a 25-year heritage in transdermal and topical drug delivery, best known for inventing the "patchless patch" metered-dose transdermal spray technology behind Evamist/Lenzetto (estradiol) and Axiron (male testosterone), the latter licensed to Eli Lilly in 2010 in a deal valued at up to US$335 million. After Axiron's commercial collapse in 2017, Acrux spent 2017–2025 building a portfolio of US generic topical products under ANDAs, achieving multiple FDA approvals but only modest licensing income. In FY2026, under new CEO John Warmbrunn, the company ceased its generic pipeline, monetised legacy assets and repositioned around a single high-value asset: a Female Testosterone Metered Dose Transdermal System for Hypoactive Sexual Desire Disorder (HSDD), a market without an FDA-approved testosterone product for women. Acrux now seeks a co-development partner to fund Phase III, while living off a small profit-share and milestone income base. --- **Company's own description.** In its FY2026 Annual Report, Acrux describes itself as a specialty pharma company with a successful track record of developing and commercialising topically applied pharmaceutical products, drawing on 25 years of experience and having marketed products through licensees worldwide with emphasis on the United States. Crucially, the FY2026 Appendix 4E and Directors' Report add that during FY26 there was "a shift of emphasis to the development of testosterone to be applied transdermally in a metered dose suitable for women and cessation of progression of the topical generic pipeline." The Annual Report's cover theme is "Female Testosterone MDTS — the catalyst to accelerate Acrux's commercial success," and management states that Acrux will pursue Female Testosterone "through licensing its intellectual property using a co-development business model." **What the company does.** Acrux formulates, develops and obtains regulatory approval for topically and transdermally applied medicines, and then out-licenses commercialisation to in-market partners. It does not manufacture at commercial scale (it uses contract manufacturing organisations; eight CMOs were contracted as at FY24) and it does not operate its own sales force. Its West Melbourne site (1,735 m²) houses laboratories, offices and warehousing, and is licensed by the TGA to manufacture certain products to clinical-trial stage. **Business model and revenue model.** Acrux is a licensing and royalty business. Its revenue model has four strands, all disclosed in FY2026 Note 4: (1) profit share and royalty income from US generic products marketed by licensees (TruPharma, Padagis) — AUD 2,948k in FY26, including AUD 829k (US$550k) from the divestment of the Prilocaine/Lidocaine cream ANDA; (2) licensing and milestone income — AUD 1,350k in FY26 from Gedeon Richter's Australian Lenzetto licence, with up to a further AUD 4,050k contingent on TGA approval and sales; (3) fee-for-service technical work for third parties — AUD 346k in FY26; and (4) "other revenue," overwhelmingly the Australian Government R&D Tax Incentive (RDTI) refundable offset — AUD 1,937k in FY26 — plus small interest income. There is no product sales revenue in the conventional sense, no subscription revenue and no service-contract backlog. On a FY2026 basis the mix was approximately 45% profit share/royalty, 20% licensing milestone, 5% fee-for-service and 30% government grant (RDTI) and interest. **Value-chain position.** Acrux sits at the upstream end of the pharmaceutical value chain: formulation science, analytical and CMC development, bioequivalence and clinical-study design, regulatory dossier preparation (ANDA, NDA/505(b)(2), TGA), device know-how (metered-dose applicators) and technology transfer. Downstream manufacturing, distribution, payer contracting and promotion are performed by partners. **Customer types.** Acrux's direct customers are pharmaceutical companies: US generic marketers (TruPharma for nitroglycerin and dapsone; Padagis for Evamist and, until December 2025, the prilocaine/lidocaine cream), a European branded women's-health company (Gedeon Richter Plc for Lenzetto in 40+ countries, and from May 2026 Australia), a Gulf distributor (Servacure Trading W.L.L. for Dapsone 5% in Saudi Arabia, July 2025), and fee-for-service clients. Prospective co-development partners for Female Testosterone are, per the FY26 Chair/CEO report, undertaking due diligence in Acrux's data room; none has been named. **End-markets.** Historically the US generic dermatology/topical prescription market (acne, anal-fissure pain, topical anaesthesia, onychomycosis) and the global menopause hormone therapy (MHT) market. Prospectively, female sexual dysfunction (HSDD) and broader women's health (premature menopause, post-cancer sexual dysfunction, potentially cognitive symptoms). **Independent characterisation.** Acrux is best understood today as a single-asset, partnering-dependent women's-health development company with a small, declining-risk royalty "annuity" attached. Its balance sheet is thin (AUD 1.7 million cash and AUD 1.5 million equity at 30 June 2026) and its FY2026 near-breakeven result (net loss AUD 604k) was enabled by non-recurring items (a AUD 1.35 million signing milestone and AUD 829k ANDA-divestment proceeds). The strategic pivot is rational given the commoditisation of US topical generics that management itself cites, but it transforms the investment case from incremental ANDA execution into a binary bet on securing a well-funded partner for a Phase III programme in an indication where several prior testosterone-for-women efforts (P&G's Intrinsa patch in Europe, BioSante's LibiGel) have failed commercially or clinically. Acrux's genuine differentiators are its heritage IP and know-how in metered-dose transdermal sprays, a completed Phase II dataset (the 90 µL dose met its primary endpoint on satisfying sexual events), existing FDA and TGA regulatory dialogue, and a long-standing relationship with Gedeon Richter, which already markets an Acrux spray in over 40 countries.

Revenue$0.0B
Employees23
Market CapN/A
Founded1998
West Melbourne, Australia
Accent

Accent Resources N.L.

Premium
Information Technology

Accent Resources NL is a Perth-based, Chinese-controlled, single-asset iron ore developer whose value rests almost entirely on the 100%-owned Magnetite Range Project (MRP) in Western Australia's Mid-West, adjacent to the former Extension Hill iron ore operation. MRP hosts a JORC 2012 Mineral Resource of 523.3Mt at 31.3% Fe, of which 106.3Mt is Measured and Indicated, with Davis Tube concentrate grades near 68–70% Fe. A Pre-Feasibility Study (PFS) has been under way since May 2025, and 2025–26 metallurgical work points to a potentially water-efficient dry magnetic separation flowsheet producing 66–68% Fe concentrate, with an optional wet polishing step reaching DRI-grade 69.7–70.3% Fe. The company is funded almost entirely by low-interest loans from its two steel-industry-linked shareholders, which together own about 84% of the shares. In July 2026 it agreed to sell its Norseman gold assets for up to A$4.0M while keeping iron ore and PGE rights and a royalty. With a free float of roughly 16% or less, the stock is extremely illiquid and volatile. --- ### What the company does Accent is a pre-revenue mineral exploration and evaluation company. Its stated principal activity in FY2024 was the exploration and evaluation of mineral deposits [AR FY24, Directors' Report]. Historically it described its focus as the discovery and development of iron ore, base metal and precious metal deposits in Western Australia [5B Jun-26 "About" boilerplate; aggregator profiles]. Since 2025 management has clearly narrowed that focus to iron ore. The July 2026 Norseman sale announcement says the company intends to concentrate financial and management resources on advancing Magnetite Range [ASX 6 Jul 2026 via Webull PDF; FNN]. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model | None operational. Income is interest on cash and term deposits ($342k FY2024; $344k interest received in FY2026 per 5B) plus trivial "other revenue" ($1k FY2024; $5k FY2025 per S&P) | | Product vs service vs subscription vs licensing mix | Not applicable: 100% of value is embedded in mineral rights and resources. A future model would be bulk commodity sales (magnetite concentrate or pellet feed) | | Value-chain position | Upstream exploration and pre-development (resource definition, metallurgy, PFS). No mining, processing, logistics or marketing assets | | Retained non-core economics | After Norseman settles: 4% gross revenue royalty over non-iron, non-PGE minerals (Boomerang may buy half for A$4.0M), plus 100% of iron ore and PGE rights over the Norseman tenure [FNN; MW; FR] | | Funding model | Related-party debt. Rich Mark and Xingang have provided concessional unsecured loans at 2.2–3.5% p.a.; total drawn facilities were A$31.125M at 30 June 2026 [5B Jun-26] | | Customer types (prospective) | Integrated steelmakers using blast furnaces (pellet feed), pellet plants, and potentially DRI/HBI producers for green-steel routes | | End markets (prospective) | Seaborne iron ore, chiefly China; the controlling shareholders are linked to Chinese steel and iron ore trading | ### Company's own description The FY2024 Annual Report describes the company as the 100% owner of the Magnetite Range project (about 350km north-north-east of Perth) and the Norseman gold project (about 5km south-east of Norseman). It says the year's work covered resource modelling, an updated global Mineral Resource estimate, heritage and environmental surveys, tenement applications and geometallurgical diamond drilling [AR FY24, Review of Operations]. The chairman's letter says the board, supported by major shareholders Rich Mark and the Xingang steel group, intends to accelerate MRP towards operation [AR FY24, paraphrased]. ### Independent characterisation Accent is best understood as a strategically controlled, shareholder-financed magnetite development option. It is not a conventional ASX junior that relies on equity raisings. Its main controller (Rich Mark, an iron ore and steel trading group) and its second holder (a subsidiary of a Henan-based steel producer) have funded the company since at least 2019 through debt, much of it at below-market rates. The accounting treats the below-market element as a "shareholder contribution" in equity [AR FY24 Notes 12, 17]. This structure has three consequences: - Ordinary shareholders have not been diluted by placements. Shares on issue rose only from 466.0M (July 2022) to 489.5M (June 2026), mainly through vested performance rights. - Debt keeps rising and finance costs dominate the income statement. - Strategic control sits with parties that may also be future offtakers, which creates potential related-party conflicts around offtake and project financing. Technically, MRP is a typical Mid-West banded iron formation (BIF) magnetite deposit: low head grade (about 31% Fe), high-quality concentrate (68–71% Fe DTR), and about 97% of the resource below the water table [5B Jun-26 resource notes]. The project's economic case will likely depend on capital intensity, water, power and port logistics, rather than on geology.

RevenueN/A
Employees2
Market CapN/A
Founded2005
Melbourne, Australia
Aarti

Aarti Surfactants Ltd.

Premium
Information Technology

Aarti Surfactants Limited is a small-cap Indian maker of surfactants and specialty ingredients for home and personal care, carved out of Aarti Industries in 2019 and listed in 2020. From two plants at Pithampur and Silvassa, with roughly 113,000 tonnes a year of capacity, it supplies sulfonation products, betaines and milder specialty ingredients to consumer-goods majors including Hindustan Unilever, Procter & Gamble, Colgate-Palmolive, Dabur and ITC. It is one of the larger merchant suppliers in India, yet a fraction of the size of the domestic leader, Galaxy Surfactants. The business is volume-rich and margin-thin: cost-plus contracts pass palm-linked feedstock prices through to customers, so revenue swings with raw materials while operating margin has stayed in a 5 to 11 percent band. Two customers supplied about 71 percent of FY2026 revenue. The investment case rests on a multi-purpose plant under construction, a new R&D centre, and a slow shift toward higher-margin specialties. --- **What the company does.** Aarti Surfactants manufactures ionic and non-ionic surfactants and specialty ingredients that go into detergents, dishwashing liquids, surface cleaners, shampoos, body washes, hand washes and skin-care formulations. The company describes itself on its website as one of the leading producers of ionic and non-ionic surfactants and specialty products, serving home and personal care, industrial applications, agro and oil industries in India and overseas. Its first annual report (FY2019) described a range of over 30 surfactants plus custom surfactants and formulated blends; the FY2025 annual report and the September 2026 AGM presentation cite 50+ products and 100+ customers. **Business model.** This is a business-to-business process-chemistry operation. The company buys oleochemical and petrochemical feedstocks (chiefly lauryl alcohol, coconut fatty acid and alpha olefin), converts them through sulfonation, sulfation, amidation and related chemistries, and sells the output in bulk to consumer-goods formulators. Crisil states that core products are largely commoditised and sold under cost-plus arrangements with quarterly price resets. That structure makes the company closer to a tolling-style converter than a price-setting specialty house: absolute profit per tonne is relatively stable, while reported revenue and percentage margin move with feedstock prices. **Revenue model.** Revenue is essentially 100 percent product sales. There is no disclosed service, subscription or licensing income. Other income is negligible in normal years; FY2025 included a one-time state industrial promotion incentive of INR 6.34 crore (Crisil). **Value chain position.** The company sits midstream, between palm- and petro-based feedstock producers (largely import-linked) and branded FMCG formulators. It does not own upstream fatty alcohol capacity and does not sell consumer brands. **Customers and end-markets.** Customers are multinational and domestic FMCG companies. CARE names Hindustan Unilever, Procter & Gamble Home Products, Colgate-Palmolive (India) and Dabur India; Crisil adds ITC. Supplier qualification takes 12 to 18 months according to Crisil, which protects incumbency. End-markets are home care (laundry, dishwash, surface care) and personal care (hair, bath, skin), with smaller sales to industrial, agrochemical and oilfield uses. Domestic sales were 82 percent of FY2026 revenue and exports 18 percent (AGM presentation summary). **Independent characterisation.** The company is best understood as the second-tier Indian merchant surfactant supplier with a concentrated blue-chip customer book, a commodity-heavy mix, and a balance sheet that has been repaired since 2022. Its strategic question is whether new capacity and R&D can lift the specialty share enough to move operating margin sustainably above the mid-single digits.

Revenue$0.1B
Employees350
Market CapN/A
Founded2018
Mumbai, India
AAKAB

AAK AB

Premium
Information Technology

AAK is a downstream, asset-flexible ingredient house that buys crude and refined plant oils — palm, palm kernel, rapeseed, shea, coconut, soybean, sunflower and exotics — and converts them into functional specialty fats sold to food, confectionery, nutrition, personal care and technical customers. Its earnings model is deliberately not a commodity-trading model: raw-material and currency exposure on contracted sales is hedged, and value is expressed as operating profit per kilo, which has risen from SEK 1.04 in 2021 to SEK 2.45 in 2025. The company is the leading global supplier of cocoa butter alternatives, holds strong regional positions in bakery, dairy-fat alternatives, foodservice and infant-nutrition lipids, and monetises refinery side-streams through its Karlshamn-based Technical Products & Feed unit. A 30.5 percent anchor shareholder (Melker Schörling AB), a net debt/EBITDA ratio of 0.68x and a decentralised co-development model with 16 customer innovation centres define its strategic character. --- **The company's own description (paraphrased from the Annual Report 2025).** AAK characterises itself as an ingredient house specialising in plant-based oils and fats, whose products are the value-adding components in consumer goods and are designed to make those goods better tasting, more nutritious, cost-efficient and more sustainable. The core of the offer is customer Co-Development: combining an understanding of each customer's needs with flexible production assets and application knowledge. The corporate purpose is expressed in the trademarked phrase "Making Better Happen". The company reports approximately 4,000 employees, about 4,000 customers, 25 sales offices, 16 customer innovation centres and 19 production plants, with net sales of SEK 46,021 million and operating profit excluding items affecting comparability of SEK 4,925 million in 2025. **Independent characterisation.** AAK is a midstream-to-downstream processor. It does not own plantations and, for most raw materials, buys from third-party crushers and refineries; it crushes and refines selected materials itself (notably rapeseed and shea at Karlshamn and Aarhus). Its competitive unit is the multi-oil refinery with fractionation, interesterification, hydrogenation-free structuring and blending capability, coupled to application laboratories. The business sells physical product by the tonne under contracts whose prices generally pass raw-material cost through to customers, which is why net sales swing with vegetable-oil prices (SEK 35.5 billion in 2021, SEK 50.4 billion in 2022, SEK 46.0 billion in 2025) while operating profit has moved on a largely independent trajectory. **Business model and revenue model.** Revenue is 100 percent product sales; there is no disclosed subscription, licensing or service revenue stream. Within product sales, management distinguishes specialty and semi-specialty solutions (co-developed, formulated, higher margin) from commodity-like single oils that fill refinery capacity. The split between these categories is not publicly disclosed as a revenue percentage; the direction of travel is disclosed qualitatively (continued higher sales of specialty solutions in every report since 2021). The company manages itself on two metrics: volume (thousand metric tonnes) and operating profit per kilo. **Value-chain position.** Upstream: farmers, plantations, shea collectors (more than 230,000 women in the Kolo Nafaso direct-sourcing programme in West Africa), mills and crushers. AAK's position: sourcing and trading, refining, fractionation and modification, formulation and application support. Downstream: fast-moving consumer goods producers, industrial bakers, dairy and plant-based food manufacturers, infant and medical nutrition companies, foodservice operators and wholesalers, cosmetics formulators, candle makers, chemical users of fatty acids and glycerine, and Nordic feed cooperatives. **Raw-material mix (share of volume in tonnes, 2025, Annual Report 2025).** Palm oil 51 percent; palm kernel oil 12 percent; rapeseed/canola oil 12 percent; the remaining 25 percent is spread across shea kernels, coconut oil, soybean oil, sunflower oil and other oils (corn, avocado, mango, grape, sesame, sal, illipe, safflower), with individual shares of 3–7 percent. The exact mapping of the smaller percentages to individual oils could not be read unambiguously from the extracted graphic and is therefore not itemised here. **Customer types and end-markets.** Chocolate and confectionery; bakery; dairy and ice cream; plant-based and new food solutions; special nutrition and health (infant, medical, senior and functional nutrition); foodservice and retail; natural emulsifiers (lecithin); personal care; technical products (fatty acids, glycerine, candle waxes); animal and fish feed. Customer concentration figures are not publicly disclosed.

Revenue$4.7B
Employees4,050
Market CapN/A
Founded1871
Malmö, Sweden
3PLearning

3P Learning Limited

Premium
Information Technology

3P Learning is an Australian-founded, globally distributed K-8 EdTech publisher. It sells subscription software for the three foundational skills of reading, writing and mathematics, and for formative assessment, to schools (B2B) and to families (B2C). Its flagship brands are Mathletics, Reading Eggs, Mathseeds, Writing Legends, Brightpath Progress and LiteracyPlanet. It serves more than 4.7 million students in over 15,000 schools across more than 140 countries, plus about 254,000 paying parent subscribers (FY26). It is a small-cap (about A$86m), founder-controlled company: Executive Chairman Matthew Sandblom's interests hold about 52% of shares, and it carries no debt. FY26 revenue was A$104.1m and underlying EBITDA was A$19.5m. After a four-year product build that followed the 2021 merger with Blake eLearning, the company says it has moved into "commercial execution". That shift has meant cost reduction, separate B2B and B2C divisions, AI-enabled productivity, blended digital-plus-print offers, and in FY26 the first dividend in 11 years. Its central challenge is persistent B2B churn in APAC. --- **Company's own description (FY26 Annual Report, paraphrased).** 3P Learning describes itself as a global market leader in EdTech programs for reading, writing, mathematics and assessment. It says its programs combine solid educational foundations with modern technology and engaging content. The Directors' Report states that the principal activity is developing, selling and marketing educational software and ebooks to schools and to parents of school-aged students, delivered as Software-as-a-Service subscriptions. The company's stated purpose is "Better Ways to Learn". **Business model.** The economics are those of a subscription-content publisher: **B2B (Business-to-School):** Schools, and in North America school districts, buy annual student licences for individual programs or bundles. The key bundle is "3 Essentials" (reading, writing and maths with single sign-on, unified rostering and cross-program reporting). Billing is concentrated in the APAC school-year cycle, so cash flow is weighted to the second half (calendar January to June). Revenue is recognised over the subscription term, which creates a deferred-revenue (contract liability) balance and delays revenue recognition. **B2C (Business-to-Consumer):** Parents buy monthly or annual subscriptions, mostly to Reading Eggs, Mathseeds and Mathletics, through the web and app stores. Apple and Google take commissions: A$5.1m of A$42.9m gross billings in FY25. Since FY25 the company also sells a premium Homeschool Max tier (US$299, about three times the basic home package), sells physical workbooks and books through eCommerce, and accepts US state Education Savings Account (ESA) funding. **Copyright licence fees:** These are statutory educational copyright receipts, mainly from the Copyright Agency Limited in Australia: A$3.1m in FY26. **Revenue mix (FY26 Directors' Report).** In FY26 about 95% of statutory revenue came from licence fees, which is subscription SaaS. Product sales (print and workbooks) sit within "other revenue" and B2C billings. They are growing fast from a small base: eCommerce Books gross billings rose 52% in FY26. **Value-chain position.** 3P Learning is a vertically integrated content creator, platform owner and distributor. It writes curriculum-aligned content, often with Pascal Press, a Sandblom-related print publisher. It builds and hosts the software, and since buying back US Reading Eggs school distribution rights from Edmentum in 2024 it sells direct in all its key regions. It relies on third-party app stores for B2C mobile distribution and on rostering and SSO platforms (Wonde, ClassLink, Clever, NSW DoE SSO) for school integration. **Customers and end-markets.** **Independent characterisation.** 3P Learning is a mature, cash-generative niche publisher with strong brands. Mathletics is a well-known maths platform in Australian, New Zealand and UK primary schools, and Reading Eggs is a widely used early-literacy app. Organic growth has been structurally weak since 2022. Statutory revenue moved from A$106.9m (FY23) to A$104.1m (FY26), while B2B churn has run at 16–18% of opening ARR and licence counts have fallen in both segments. The investment case has shifted from growth to cash yield and turnaround. Margins have been rebuilt through cost-out and a material government grant, the Digital Games Tax Offset (DGTO). Growth now hinges on three things: the NZ Ministry contract (calendar 2027–2029), US districts and homeschool, and blended print/digital bundles that use the controlling shareholder's print publishing capability.

RevenueN/A
Employees310
Market CapN/A
Founded2003
which was not retrieved, Australia
360

360 Capital REIT

Premium
Information Technology

360 Capital REIT is a small-capitalisation, externally managed Australian diversified REIT that owns a A$202.4m portfolio of three modern, fully leased commercial assets on the east coast: a 50% interest in an office/healthcare building at 510 Church Street, Cremorne (Melbourne); an A-grade Commonwealth-anchored office building at 38 Sydney Avenue, Forrest (Canberra); and a high-tech industrial headquarters at 34 Southgate Avenue, Cannon Hill (Brisbane), leased to Michael Hill International. Since February 2026 its stated strategy combines this stable "passive" rental base with up to 25% of balance-sheet capital in short-dated structured and preference-equity investments targeting 15–20% returns. The first such investment is a A$10.0m, 16% coupon position over a Sydney apartment block. TOT is controlled (c. 51%) by entities of its manager's Executive Chairman, Tony Pitt. It trades at a c. 29–31% discount to NTA, which management aims to close through earnings growth, tax-deferred distributions and a carried franking balance. --- ### What the company does TOT is a listed property trust whose economic activity consists of owning income-producing real estate and, increasingly, investing in structured real-estate equity. Its revenue is overwhelmingly contractual rent. In FY26, rental income (including straight-lining and recoverable outgoings) was A$15.293m of A$16.244m total revenue (94.1%). Finance revenue was A$0.940m (5.8%), almost entirely the 16% coupon accrued on loan notes issued by 360 Capital Private Equity Fund 1 (PEF1). Distribution income was A$0.011m (FY26 Annual Report, Note 3). ### Company's own description (paraphrased from the FY26 Annual Report) The Responsible Entity describes the Fund's strategy as investing in real estate equity. Its focus is a diversified portfolio of well-leased, income-producing commercial real estate across Australia. It complements this with "active" investment opportunities intended to enhance the returns of the stable passive portfolio. The FY26 Results Presentation frames the model as a A$202.4m core of modern office, industrial and healthcare assets anchored by Government and ASX-listed tenants. Alongside sits up to 25% of the balance sheet in short-dated, downside-protected structured equity, which together lift the blended investment yield from 6.4% to 6.9%. ### Business model and revenue model | Revenue stream | FY26 (A$k) | % of total | Nature | |---|---|---|---| | Base rental income | 12676 | 78.0 | Contracted lease income; 93.8% fixed reviews, 6.2% CPI-linked with floors | | Rent straight-lining (non-cash) | 738 | 4.5 | Accounting adjustment; excluded from operating profit | | Recoverable outgoings | 1879 | 11.6 | Pass-through of building operating costs to tenants | | Interest on PEF1 loan notes | 873 | 5.4 | 16% p.a. capitalised coupon (non-cash until repaid) | | Interest on cash | 67 | 0.4 | Bank interest | | Distribution from unlisted units | 11 | 0.1 | PEF1 preference units | | Total revenue | 16244 | 100.0 | — | Source: FY26 Annual Report, Note 3. In product/service/subscription/licensing terms, TOT's revenue is 100% "service-like" recurring lease income plus investment income. It has no product sales, subscription or licensing income. ### Value-chain position TOT sits at the capital-provider/landlord end of the commercial real estate value chain. It does not develop, construct or operate assets. Property and asset management, leasing, transactions and capital management are outsourced to the 360 Capital platform, which earns fees. In structured equity, TOT ranks between senior bank debt and ordinary equity in the PEF1 capital structure. It receives a fixed 16% coupon ahead of ordinary equity, plus a 20% profit share above a hurdle (FY26 Results Presentation, p.16). ### Customer types and end-markets | Customer / end-market | Share of direct-portfolio income (FY26) | Examples | |---|---|---| | Australian Government (Commonwealth) | 41.2% | ANAO, ACIAR (38 Sydney Ave); NDIA (510 Church St) | | ASX-listed / public companies | 43.1% | Michael Hill International, Monash IVF, Endeavour Group, Dentsu (parent listed in Tokyo), Siemens Energy (listed in Frankfurt) | | Private companies | 15.8% | SRC Australia, Kane, TGI Sport Marketing, Stack Infrastructure, CropLife, café operator | Source: FY26 Results Presentation, p.10. Sector exposure by value (including structured equity): office/healthcare 47.7%, office 32.2%, high-tech industrial 15.0%, residential (structured equity) 5.1%. ### Independent characterisation TOT is best understood as a sub-A$100m market-cap, high-gearing (38.9%), three-asset REIT with concentrated tenant exposure. The top tenant, the Commonwealth, accounts for 35.0% of direct income, and the top two tenants for about half. Its distinguishing features are not scale or diversification. They are (i) a young, energy-efficient portfolio needing little capex; (ii) tax attributes, namely c. A$5.0m of franking credits in the Active REIT and depreciation-driven tax-deferred distributions; (iii) a related-party "active" overlay giving access to 360 Capital-originated structured deals; and (iv) a controlling securityholder who is also the manager's principal. This last feature aligns interests but also concentrates governance and related-party risk.

RevenueN/A
Employees24
Market CapN/A
Founded2015
Sydney, Australia
1300SMILES

1300SMILES Limited

Premium
Information Technology

1300SMILES Limited is a regional-Queensland-anchored dental services organisation (DSO). It built a 33-practice network concentrated in Queensland's ten largest population centres plus a small New South Wales presence. Its model is service-centric. The company owns the surgeries, equipment and support staff and provides billing, marketing, accreditation and procurement. Self-employed dentists practise inside its facilities under Dental Service Agreements and pay the company a share of their production. For two decades under founder Dr Daryl Holmes, the company was distinctive among ASX dental roll-ups for its conservatism: modest leverage, owner-like capital allocation, uninterrupted fully franked dividends from listing, and a disciplined, opportunistic approach to acquisitions. That record culminated in a FY2021 result of A$65.8m over-the-counter revenue and A$9.6m NPAT. It then sold to BGH Capital and OTPP-backed Abano Healthcare at 13.5x underlying pre-AASB 16 EBITDA. Today it is a regional brand inside one of Australasia's largest dental platforms. --- ### Company's own description (Annual Report FY2021, paraphrased) 1300SMILES described itself as the owner and operator of full-service dental facilities in New South Wales and in Queensland's ten major population centres. It stated an intention to expand into other Australian regions, both by opening its own sites and by acquiring established practices. Corporate and administrative functions sit in Townsville. The operating model works as follows: - The company provides dental surgeries, practice management and related services to self-employed dentists who run their own practices. - Those dentists pay fees under a Dental Service Agreement. - In some cases the company employs dentists directly. Services provided to dentists include: - Marketing - Administration - Billing and collections - Facility certification and licensing - All support staff, equipment and facilities - Group-level purchasing of consumables The dentist base ranges from new graduates to experienced practitioners. Some have special interests in endodontics, oral surgery, implants and periodontics and cross-refer within the network. The stated growth drivers (Annual Report FY2021) were: 1. Attracting more dentists to existing facilities and expanding those at full capacity. 2. Lifting the turnover of existing dentists through benchmarking, training and mentoring. 3. Greenfield practices in existing and new regions. 4. Acquiring substantial practices on favourable terms. 5. Managing dental facilities owned by others. ### Independent characterisation **Business model.** 1300SMILES is best understood as a dental infrastructure-and-services landlord with operating leverage, not a clinical provider in the accounting sense. The economic engine is the gap between over-the-counter (OTC) patient billings and what the company retains after dentists take their share. The company reported both measures. In FY2021: - OTC revenue (total patient fees billed through its practices) was A$65.8m. - A$20.8m was retained by self-employed dentists. - Statutory revenue was therefore A$44.9m. The implied company retention ratio was about 68% of OTC billings (derived). This is consistent with a model where the company carries the full fixed cost base (staff, premises, equipment, consumables), and the dentist's share is effectively a variable cost. **Revenue model mix (FY2021, Note 5 and Note 6).** - Services, in the form of DSA service fees: 96.8% - Financial and other income: 3.2% - Product, subscription and licensing revenue: not material as separate lines A membership/treatment-plan revenue stream (the "$1-a-day Dental Care Plan") was recognised over time. It was disclosed only within receivables (A$0.2m at 30 June 2021), not as a separate revenue line. **Value chain position.** 1300SMILES sits between upstream suppliers and downstream payers: - Upstream: dental consumables and equipment suppliers, dental labs, landlords, and the dentist labour market. - Downstream: patients and payers, including out-of-pocket patients, private health insurers (the website lists preferred-provider relationships with Medibank, nib, Bupa, HCF, CBHS, Westfund, Defence Health and TUH), and the Commonwealth Child Dental Benefits Schedule (CDBS). **Customer types.** The company has two customer classes: - Dentists, who are the contractual customers paying service fees. - Patients, who are the economic end-users: families, children (CDBS), adults seeking general, restorative and cosmetic care, and regional populations under-served by public dental services. **End-markets.** The end-market is Australian private general dental services, with a regional Queensland focus (Townsville, Cairns, Mackay, Rockhampton, Gladstone, Bundaberg, Toowoomba, the Sunshine Coast and Greater Brisbane) and a small Sydney footprint (Cammeray).

RevenueN/A
Employees338
Market CapN/A
Founded1991
Townsville, Australia
NLCIndia

NLC India Ltd

Premium
Information Technology

NLC India occupies a structurally unusual position in the Indian energy complex: it is simultaneously a fuel producer and a regulated generator, capturing margin at both ends of a vertically integrated lignite-to-electron chain that no other listed Indian company replicates at scale. Roughly 55% of national lignite output is its own. Its pit-head thermal fleet enjoys near-zero fuel logistics cost and CERC-regulated returns, giving the group an annuity-like cash base that funds an unusually aggressive diversification programme. Management is converting that base into a three-vector growth story: commercial thermal coal (Talabira, Machhakata, Pachwara South, North Dhadu), 10 GW of renewables by 2030 housed in a listing-bound subsidiary, and an early-stage nuclear option with NPCIL. The equity is therefore best understood not as a lignite utility but as a state-sponsored energy-transition holding company, with the attendant execution, leverage and governance risks of a ₹1.17 lakh crore capital plan. NLC India Limited is a Navratna Central Public Sector Enterprise under the administrative control of the Ministry of Coal, Government of India. It is India's only integrated lignite-mining-to-power utility of national scale, and over the past decade it has extended that franchise into thermal coal mining, utility-scale renewables and, most recently, nuclear power development. ### Market capitalisation and headcount | Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---| | Total manpower including subsidiaries (persons, at 31 March) | 0 | 0 | 10368 | 10227 | 0 | | Market capitalisation at latest available date (INR crore) | 0 | 0 | 0 | 0 | 37862 | *Note on the table above: manpower figures for FY2022, FY2023 and FY2026 are not publicly disclosed in the sources retrieved and are entered as 0 to preserve the chartable format; they should not be read as zero. The FY2024 and FY2025 figures are from the Directors' Report ("total manpower strength, including subsidiaries, stood at 10,227 employees as on 31st March 2025 as against 10,368 as on 31st March 2024"). A third-party workforce-analytics vendor (Revelio Labs) estimates a materially lower headcount of approximately 8,150 as at March 2026 on a different methodology (professional-profile-derived, excluding non-executive/unionised workmen); the company's own disclosure is the authoritative figure and the two are not comparable.* **Current market data (close of 4 September 2026):** share price ₹273; market capitalisation ≈ ₹37,862 crore; consolidated book value per share ≈ ₹155; consolidated trailing P/E ≈ 11.8x; dividend yield ≈ 1.32%; consolidated trailing ROE ≈ 17.5%; consolidated ROCE ≈ 10.4%. The 52-week trading range is reported by Screener as ₹388/₹228. The company separately stated that its shares "touched an all-time high market price of ₹336.50 per share on the NSE on 11 May 2026, taking market capitalisation beyond ₹46,660 crore." Discrepancy flagged: the ₹388 high and the ₹46,660 crore market capitalisation implied by ₹336.50 are mutually inconsistent with a ₹37,862 crore capitalisation at ₹273; the ₹46,660 crore figure appears to be a company arithmetic or reporting inconsistency (138.66 crore shares × ₹336.50 ≈ ₹46,660 crore is arithmetically correct, so the inconsistency lies in the ₹388 52-week high, which would imply a ~₹53,800 crore peak capitalisation). Both are recorded here without adjudication. --- ### The company's own characterisation In its filings, NLC India describes itself as "engaged in the business of mining of lignite, coal and generation of power by using lignite as well as renewable energy sources and consultancy." Its stated segments are Mining (lignite and coal) and Power Generation (thermal and renewable), with power sold to power utilities across the country. The company's mission statement, as reproduced in public policy commentary, frames the business as "integrating People, Planet and Profit through sustainable mining and green energy leadership." ### Independent characterisation NLC India is, in economic substance, four businesses stacked on one balance sheet: **(i) A captive lignite mining utility.** Three opencast lignite mines at Neyveli, Tamil Nadu (Mine-I, Mine-IA, Mine-II) with an aggregate sanctioned capacity most recently disclosed at 28 MTPA (some earlier company disclosures and press summaries cite 30 MTPA for the Neyveli complex — discrepancy flagged), plus one opencast lignite mine at Barsingsar, Rajasthan, at 2.10 MTPA. Substantially all lignite is consumed captively by adjacent pit-head thermal stations; a small merchant volume is sold to third parties. Because the mines sit directly beside the boilers, NLC avoids the rail-freight and washery economics that dominate Coal India's cost structure — a durable structural advantage — at the cost of being geographically immobile and land-constrained. **(ii) A regulated thermal generator.** Four lignite-fired stations at Neyveli aggregating 3,390 MW (Thermal Power Station-I Expansion 420 MW, Neyveli New Thermal Power Project 1,000 MW, Thermal Power Station-II 1,470 MW, TPS-II Expansion 500 MW) and one 250 MW lignite station at Barsingsar, Rajasthan — 3,640 MW on a standalone basis. Tariffs are determined by the Central Electricity Regulatory Commission on a cost-plus regulated-return basis under multi-year tariff regulations, with capacity charges recovered against availability rather than dispatch. This is the annuity core of the enterprise. Power is sold under long-term PPAs principally to southern-region distribution utilities — Tamil Nadu, Kerala, Karnataka, Andhra Pradesh, Telangana, Puducherry — plus Rajasthan for Barsingsar. **(iii) A commercial coal miner.** Talabira II & III opencast project in Odisha (20 MTPA installed capacity, ramping) delivered a record 19.14 MT in FY2026. Pachwara South (9 MTPA normative / 13.5 MTPA peak, Jharkhand, held through NUPPL) began production in March 2026. Two commercial blocks won at auction — North Dhadu Western Part (3 MTPA) and Machhakata, Odisha (30 MTPA, ~1.4 billion tonnes of reserves) — take the sanctioned pipeline toward the stated 100+ MTPA-by-2030 mining ambition. This is the segment that changes NLC's identity most: commercial coal is merchant-priced, not regulated, and introduces genuine commodity beta to a previously regulated earnings stream. **(iv) A renewables platform in the process of being carved out.** Approximately 1,431 MW of operating solar and wind at the start of FY2026, rising to roughly 1,734–1,766 MW after FY2026 additions (minor discrepancy between sources flagged). These assets are being transferred into NLC India Renewables Limited (NIRL), a wholly owned subsidiary incorporated 14 June 2023, ahead of a planned IPO in which up to 25% would be divested. ### Revenue model NLC has no subscription or licensing revenue of consequence. The mix is: **Regulated capacity and energy charges:** (dominant): two-part tariffs from lignite thermal stations under CERC regulations, comprising fixed/capacity charges recovered on declared availability and energy charges passing through fuel cost. This produces high revenue visibility and low volume risk, but caps upside and exposes the company to regulatory lag — NLC has continued to bill on the 2019-24 tariff order pending finalisation of the 2024-29 order, creating a rate-regulated receivable/deferral that materially distorts reported tax and profit lines. **Merchant and PPA-based coal sales:** commercial coal volumes sold at auction-linked or notified prices. **Lignite sales to third parties:** a small, historically ~₹400 crore-scale line. **Renewable energy sales:** under 25-year fixed-tariff PPAs with SECI, NCRTC, state utilities and others — long-duration, inflation-unlinked, but very low operating cost. **Consultancy services:** mine planning, mine construction, and renovation/life-extension of older power stations, offered to third-party miners and utilities. Immaterial to group revenue but strategically useful for retaining engineering capability. **Power trading:** a small licensed activity. ### Value chain position and customer types NLC sits upstream (fuel extraction) and midstream (generation) and does not participate in transmission, distribution or retail. Its customers are therefore almost exclusively state-owned distribution companies and central intermediaries — TANGEDCO, Kerala SEB, Karnataka's ESCOMs, Telangana and Andhra discoms, Puducherry Electricity Department, UP discoms (via NUPPL), Odisha's GRIDCO, Rajasthan discoms, plus SECI and NCRTC for renewables. This concentration in state-utility counterparties is the single most important structural credit consideration: historical receivable stretch drove consolidated debtor days to 301 in FY2020. Aggressive collection discipline and the central government's Late Payment Surcharge Rules have since compressed this to 70 days in FY2026, with the company reporting 100% collection efficiency from power debtors for FY2026 and 118.96% (i.e., including arrears recovery) for the nine months to December 2025. ### End-markets Baseload electricity for the Southern Region grid (its historic franchise), the Northern Region (via Ghatampur), and increasingly the national renewables market. Secondary end-markets in development: green hydrogen (a 4 MW PEM electrolyser project at Neyveli), manufactured sand from mine overburden ("wealth from waste"), critical minerals, and — following the SHANTI legislation of December 2025 — nuclear generation.

Revenue$2.0B
Employees2,022
Market CapN/A
Founded1956
Tamil Nadu, India
Zip

Zip Co Ltd

Premium
Information Technology

Zip Co Limited is a two-market digital consumer credit and payments platform that has completed one of the more decisive turnarounds in global fintech. Having abandoned a fifteen-country expansion strategy that produced a cumulative statutory loss in excess of AUD 2.1bn between FY2021 and FY2023, Zip now operates only in the United States and Australia, and has delivered twelve consecutive quarters of group profitability through FY26. The economic centre of gravity has shifted decisively: the United States generated 76% of FY26 total transaction volume and roughly 85% of divisional cash earnings. Zip's differentiation rests on a two-sided revenue model — it charges both merchants and consumers — which produces a revenue margin of roughly 8% of transaction volume, materially above pure merchant-funded pay-in-four peers. The company is now attempting a second transition: from a single-product instalment lender to a multi-product short-term cash-flow platform covering bills, rent, income smoothing and an all-access card. | Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Employees (headcount, all controlled subsidiaries) | n/d | 742 | 877 | FY2024 headcount is not disclosed in the sources consulted. The FY2025 figure of 742 is from the IBISWorld company register (drawn from statutory filings); the 877 figure is the S&P Global Market Intelligence count as at September 2026. The two series may be constructed on slightly different bases (period-end versus average, and treatment of contractors), so the implied ~18% year-on-year increase should be treated as indicative rather than as a disclosed company metric. --- ### The company's own characterisation Zip describes itself on its investor relations landing page as follows: "ASX-listed Zip Co Limited (ASX: ZIP) is a digital financial services company, offering innovative and people-centred products. Operating in two core markets – Australia and New Zealand (ANZ) and the United States (US), Zip offers access to point-of-sale credit and digital payment services, connecting millions of customers with its global network of tens of thousands of merchants." The company's stated purpose, repeated in results materials since FY24, is "unlocking financial potential, together." In US-facing communications Zip positions itself as serving "everyday Americans" and, more pointedly, the "financially underestimated" — a deliberate framing of its core demographic as consumers underserved by prime credit-card underwriting rather than as subprime borrowers. Note that the ANZ framing is now partially historical. On 16–17 July 2026 Zip announced an orderly wind-down of its New Zealand operations following a strategic portfolio review, stating that the financial impact would be immaterial to the group. The operating perimeter from FY27 is therefore effectively Australia and the United States. ### Independent characterisation Zip is best understood not as a payments company but as a short-duration unsecured consumer lender with a payments distribution layer. Three structural features define the economics. **First, the balance sheet is the product.** Zip originates receivables and funds them through warehouse facilities, master trusts and rated note issuance. Total debt of approximately AUD 2.76bn at the FY26 balance date is overwhelmingly receivables funding rather than corporate leverage; corporate debt was fully repaid in FY25 following a AUD 267m equity raise. Consequently the two variables that determine whether Zip earns anything are the cost of funds (6.74% in FY26, down from 7.27% in FY25) and the net loss rate (1.8% of TTV group-wide in FY26). Neither is controllable in a downturn, which is the principal reason the equity trades with a five-year beta of 3.24. **Second, the revenue model is two-sided and this is genuinely differentiating.** Unlike Afterpay or Klarna's pay-in-four, which are predominantly merchant-funded, Zip earns from both counterparties: merchant service fees, consumer account-keeping fees, transaction fees, instalment fees and, in Australia, interest and portfolio yield on the Zip Money and Zip Plus lines (Australian portfolio yield of 19.0% in FY26). This produces a group revenue margin of 8.1% of TTV in FY26 — roughly two to three times the take-rate of a merchant-funded pay-in-four business. The trade-off is that the consumer-fee component attracts materially more regulatory attention, and Australia's June 2025 licensing regime was designed precisely around this fee architecture. **Third, the two geographies are different businesses.** The Australian book is a revolving line-of-credit product with a long-duration receivable (AUD 2,307.0m of Australian receivables at 30 June 2026), regulated under the National Credit Code, funded domestically at low margins, and earning a 19.0% yield with an excess spread of approximately 8.4%. The US book is a short-duration instalment product with an average duration of roughly seven weeks, an average order value of USD 141, and a net transaction margin of roughly 3.5% — a velocity business rather than a yield business. Group cash net transaction margin of 3.9% is the blended output of a ~5.5% ANZ margin and a ~3.5% US margin, which means that as the US mix rises, the group revenue margin mechanically declines (it fell 17 basis points to 8.1% in FY26 for exactly this reason). Investors who read declining revenue margin as deteriorating unit economics are misreading a mix effect; investors who read it as costless are ignoring that operating margin expansion has had to run faster than mix dilution to compensate. ### Revenue model composition | Revenue driver | Nature | Geography | Disclosure basis | |---|---|---|---| | Merchant service fees | % of transaction value paid by merchant | US and ANZ | Aggregated in "total income" | | Consumer account fees | Monthly account-keeping fees | Primarily ANZ | Aggregated | | Instalment / transaction fees | Per-transaction consumer fee | Primarily US | Aggregated | | Portfolio interest / yield | Interest on Zip Money and Zip Plus balances | Australia (19.0% portfolio yield FY26) | Disclosed as portfolio yield | | Late / dishonour fees | Consumer penalty fees | Both | Not separately disclosed | | Other income | Interest on cash, sundry | Group | Difference between total income (1,347.4) and revenue from ordinary activities (1,336.0) in FY26 | Zip does not disclose a full product-level revenue split. The disclosed components are: There is no subscription revenue line and no licensing revenue line. Zip is not a SaaS business and should not be valued as one. ### Value chain position and customer types Zip sits between the acquirer/PSP layer and the consumer. It does not own the merchant relationship end-to-end in most of its US volume — increasingly it is distributed as a payment method inside third-party checkout infrastructure (Stripe, Primer, IXOPAY). This is a strategically double-edged position: distribution scales without direct sales cost (US merchant count grew 24.6% to 30.8 thousand in FY26 largely through the Stripe general-availability integration), but Zip becomes one tile in a checkout it does not control, competing on conversion against Affirm, Klarna, Afterpay and PayPal in the same interface. Customer types are: (i) consumers, 6.5m active group-wide at FY26 (4.6m US, balance ANZ), skewing toward younger and thinner-file borrowers, with 45% of US customers already using Zip to pay bills and 60% renters; (ii) merchants, 97.4 thousand accredited group-wide at FY26, ranging from enterprise (The Iconic, Samsung, Expedia Group, GameStop, Vivid Seats, Major League Baseball retail and ticketing) to long-tail SME reached through PSP integrations; (iii) funding counterparties — warehouse banks, note investors and, since FY26, the RBA repo-eligible market for two AAA-rated Australian notes. End-markets served span discretionary retail (fashion, electronics, home) and, increasingly, non-discretionary categories. In FY26 the fastest-growing US verticals were insurance and utilities (+56% year-on-year), food and beverage (+50%) and household goods (+38%). Management frames this diversification as cash-flow smoothing through the cycle; it is also, less charitably, a shift toward customers financing consumption staples, which is a different credit proposition from financing a discretionary purchase.

RevenueN/A
Employees877
Market CapN/A
Founded2017
New South Wales, Australia
Vodacom

Vodacom Group Ltd

Premium
Information Technology

Vodacom Group is the largest telecommunications and mobile financial services operator on the African continent by consolidated customer base and, since 30 June 2026, the controlling shareholder of Safaricom Plc. Majority-owned (65.1%) by Vodafone Group Plc, Vodacom operates controlled mobile networks in South Africa, Egypt, Tanzania, the Democratic Republic of Congo, Mozambique and Lesotho, and — following consolidation — Kenya and Ethiopia. At 31 March 2026 the Group served 237.3 million customers and 103.0 million financial services customers across eight markets, with networks covering 595.8 million people. Its differentiating asset is not connectivity alone but the largest mobile-money franchise in Africa: M-Pesa, Vodafone Cash and VodaPay together processed US$547.9 billion of transaction value in the twelve months to June 2026. The investment case rests on a mature, cash-generative South African business funding high-growth exposure to Egypt, East Africa and financial services, under an explicit Vision 2030 revenue ambition of more than R300 billion. --- ### The company's own description In its FY2026 investor materials Vodacom describes itself as "a leading and purpose-led African connectivity, digital and financial services company" whose purpose is "to connect for a better future." Management frames the business around three Vision 2030 strategic imperatives: differentiate with customer experience; innovate for growth; and invest in strategic enablers of growth and efficiency. The three purpose pillars are empowering people, protecting the planet and maintaining trust. Management has explicitly recast the corporate identity away from "telco" toward "TechCo," a transition first articulated under the Vision 2025 strategy and carried into Vision 2030. ### Independent characterisation Vodacom is best understood as three structurally distinct businesses stapled together by a common brand licence, a shared technology stack and a common capital allocator. **First, a mature South African mobile incumbent.** South Africa generated R92.6 billion of revenue and R64.4 billion of service revenue in FY2026 — 55% and 48% of group totals respectively — at a 35.6% EBITDA margin. Growth here is low single digit (2.1% service revenue in FY2026, 2.0% in Q1 FY2027). This is the cash engine, not the growth engine. It funds group dividends and carries the balance sheet. **Second, a high-growth emerging-market connectivity portfolio.** Egypt (36.2% local-currency service revenue growth in FY2026) and the International segment (14.4% normalised) supply the growth. Egypt alone contributed 29.7% of group EBITDA in FY2026 on 27.0% of service revenue — a higher-margin, higher-growth asset than the home market, which is unusual for an emerging-market acquisition and validates the December 2022 purchase. **Third, a pan-African fintech.** Financial services revenue of R16.8 billion (FY2026, +19.6%) contributed 12.6% of consolidated service revenue. With Safaricom consolidated from 1 July 2026, management expects that contribution to rise above 22% — a step-change that makes Vodacom, on a consolidated basis, one of the largest financial-services-by-revenue franchises listed on the JSE outside the banks. ### Revenue model and mix | Revenue category (ZAR M) | FY2025 | FY2026 | % of FY2026 revenue | |---|---|---|---| | Service revenue | 120734 | 133561 | 79.7 | | Equipment revenue | 20173 | 20268 | 12.1 | | Non-service revenue | 9872 | 12293 | 7.3 | | Interest income recognised as revenue | 663 | 671 | 0.4 | | Other revenue (mainly IFRS 16 lease revenue) | 785 | 859 | 0.5 | | Total revenue | 152227 | 167652 | 100.0 | Vodacom's revenue is overwhelmingly recurring service revenue rather than product sales or licensing. In FY2026: Within service revenue, the FY2026 split by product was: mobile prepaid R78,298m; mobile contract R34,146m; fixed service R8,919m; other service revenue R7,235m; mobile interconnect R4,963m. Prepaid dominance (58.6% of service revenue) is the defining structural feature of the African model and explains the sensitivity of the business to consumer disposable income and to prepaid recharge behaviour. **Subscription vs. transactional.** Contract (post-paid) revenue is genuinely subscription-based; prepaid is transactional and repriced continuously through "nano-pricing" personalisation (the Just4You platform). Financial services revenue is fee- and commission-based, plus interest income on lending and float. Equipment revenue is device sales, largely pass-through at low margin, and is deliberately grown to drive smartphone penetration (68.6% at FY2026) rather than for its own economics. ### Value chain position and customer types Vodacom sits at the retail and wholesale connectivity layer, increasingly integrating downstream into financial services, digital services and enterprise IT, and — through the Maziv associate stake — upstream into passive fibre infrastructure. It is a buyer from network equipment vendors (Nokia, Ericsson, Huawei), handset OEMs and tower companies, and a seller to: **Consumers:** (the overwhelming majority): prepaid and contract mobile, mobile data, fixed broadband, mobile money, insurance and lending. **Small and medium enterprises and large corporates:** via Vodacom Business: connectivity, cloud, hosting and security (CHS revenue +27.1% in FY2026 in South Africa), IoT (9.9 million connections in South Africa at June 2026), managed services and financial solutions. Vodacom Business Africa markets to enterprises across 32 countries. **Governments and public sector:** national relay services, health, education and utility solutions (the RT29 tender win in South Africa drove 17.5% IoT revenue growth in Q1 FY2027). **Wholesale carriers and ISPs:** carrier services, national roaming, transit and bitstream. **Merchants:** 716,000 M-Pesa merchants across the International business at June 2026; over 11,200 in South Africa. ### End-markets served Eight operating markets: South Africa, Egypt, Tanzania, DRC, Mozambique, Lesotho, Kenya and Ethiopia. Aggregate population coverage 595.8 million (FY2026). The demographic thesis is straightforward: young populations, low fixed-line penetration, low banking penetration and rising smartphone affordability. Management's own framing is that "the challenge is increasingly one of device access rather than coverage."

Revenue$9.3B
Employees2,026
Market CapN/A
Founded1993
Gauteng, South Africa
SBI

SBI Holdings Inc

Premium
Information Technology

SBI Holdings is Japan's dominant challenger financial conglomerate and, on the evidence of FY2025, its most profitable large securities-led group. Built from a 1999 SoftBank venture-capital spin-out, it has assembled an internet-native "financial ecosystem" — SBI SECURITIES (the largest retail brokerage in Japan by accounts and individual trading share), SBI Shinsei Bank, an insurance group, a top-ten asset manager, a private-equity franchise, and the country's largest regulated crypto-asset platform — and is now bolting on two adjacent ecosystems: a "digital space" ecosystem built around on-chain finance, and a "Neo-media" ecosystem of IP, talent and advertising assets. In FY2025 it earned JPY 516.7bn pre-tax on JPY 1,896.6bn of revenue and a 28.0% ROE, overshooting its own FY2028 targets three years early. The strategic bet is unusually explicit: that finance moves on-chain, that AI agents intermediate it, and that whoever owns the customer base and the rails captures the economics. | Metric | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---| | Employees (consolidated, headcount) | 18756 | 19097 | 19156 | 18669 | | Employees at overseas locations (%) | 21.7 | 20.3 | 22.7 | 0 | | Overseas employee ratio (%) | 37.7 | 35.5 | 37.0 | 0 | | Female employees (headcount, dom+ovs consolidated) | 8133 | 8287 | 8381 | 0 | | Ratio of female employees (%) | 43.4 | 43.4 | 43.8 | 0 | *Source: SBI Holdings Integrated Report 2025 Fact Sheet (FY2022–FY2024). FY2025 headcount of 18,669 is taken from MarketScreener's company profile and is not confirmed against a primary filing; zeros in the FY2025 column denote "not publicly disclosed" in the sources reviewed rather than a value of nil. SBI itself notes headcount is not strictly continuous year to year because of M&A and methodology changes.* --- ### What the company does SBI Holdings is a pure holding company. It owns and operates a very large federation of financial and quasi-financial businesses — by SBI's own count, 721 consolidated and equity-method entities as at the end of March 2024 (595 consolidated subsidiaries, 64 consolidated partnerships, 62 equity-method companies), of which 18 were separately listed including SBI Holdings itself (source: FY2024 results presentation, 9 May 2025). That number has grown further with the FY2025 acquisition programme. The company's own framing, used consistently across its investor materials, is that it operates a "financial ecosystem" in which each business feeds customers, data and product to the others, and that this ecosystem is now merging with a "digital space ecosystem" (crypto, stablecoins, security tokens, blockchain infrastructure) and a newly built "Neo-media ecosystem" (media, IP, talent, advertising). Management's stated logic is that customer contact points propagate across the three ecosystems, lowering acquisition cost and raising lifetime value across all five reporting segments. ### Independent characterisation Stripped of the corporate language, SBI is four quite different businesses stapled to a fifth optionality bucket: 1. **A retail distribution utility.** SBI SECURITIES, SBI Shinsei Bank, SBI Insurance Group and SBI MONEYPLAZA collectively hold a customer base SBI puts at 54.42m (end-March 2025) and a securities account base that crossed 16m in May 2026. Since the September 2023 "ZERO Revolution" eliminated online domestic equity commissions, this business no longer monetises trading; it monetises float, margin lending, investment-trust fees, foreign equities, bonds, FX and cross-sell. This is the profit engine. 2. **A balance-sheet bank.** SBI Shinsei Bank, consolidated since December 2021, is a JPY 18.0tn operating-asset lender (end-March 2026) spanning housing loans, APLUS consumer finance, structured finance, corporate lending and overseas (UDC Finance in New Zealand, Latitude in Australia). It relisted on TSE Prime in December 2025. 3. **A principal investment book.** The PE Investment Business carried JPY 1,107.0bn of private equity and related exposure as at end-March 2026, heavily concentrated in digital assets/blockchain (JPY 436.9bn) and internet/AI/IoT (JPY 197.4bn). Its earnings are mark-to-market and therefore volatile — this is the single largest source of reported-earnings noise in the group. 4. **A crypto-asset infrastructure business.** SBI VC Trade (post-merger with BITPOINT Japan), B2C2 (institutional market making, UK), plus the pending Bitbank and completed Coinhako acquisitions. 5. **Everything else (Next Gen).** Biotech/5-ALA, healthcare informatics, semiconductors, Web3 ventures, and the Mynavi equity stake. ### Revenue model SBI does not disclose a product-versus-service-versus-subscription revenue mix. Reconstructing from segment and subsidiary disclosure, the FY2025 revenue base is dominated by: **Net interest and financial revenue:** banking net interest income, margin-lending financial revenue at SBI SECURITIES (JPY 120.5bn in FY2025, +41.1% YoY), and the loan books at SBI SAVINGS BANK, APLUS and UDC. **Asset-based recurring fees:** investment trust fees at SBI SECURITIES (JPY 25.4bn in Q4 FY2025 alone, a record), management fees at SBI Global Asset Management (JPY 12.1tn AUM at end-March 2026), and wrap/advisory fees. **Transaction and intermediation commissions:** foreign equities, futures/options, bonds (SBI SECURITIES sold JPY 87.0bn of retail JGBs in the July–Dec 2025 window, ranking second among brokers), underwriting and IPO distribution. **Insurance premiums:** SBI Insurance Group ordinary revenue of JPY 140.4bn in FY2025. **Trading and market-making:** SBI Liquidity Market (FX infrastructure), B2C2. **Investment gains and fair-value changes:** JPY 91.0bn in FY2025 within the PE segment. **One-off capital gains:** most materially the JPY 141.6bn gain on the sale of SBI Sumishin Net Bank in Q3 FY2025. ### Value chain position and customers SBI is unusual among Japanese financial groups in occupying the *whole* chain in several product lines simultaneously: it manufactures product (SBI Asset Management, SBI Insurance, SBI Shinsei Trust & Banking as stablecoin issuer), operates market infrastructure (Japannext PTS, Osaka Digital Exchange, SBI Liquidity Market, AsiaNext, DigiFT JV), and distributes to end investors (SBI SECURITIES, SBI MONEYPLAZA, bank branches). It is also a wholesale supplier to third parties — BaaS, financial-instruments intermediation for SMBC's Olive, and system/DX services to regional financial institutions through Wealth Advisor and the SBI Regional Bank Holdings network. Customer types: Japanese retail investors and savers (the core), high-net-worth individuals via the SBI Shinsei Wealth Management joint branches (assets under management there passed JPY 1tn on 23 April 2026), domestic and global institutional investors (SBI SECURITIES' institutional revenue is up roughly 2x in five years and trading value more than 3x, indexed from FY2021), corporates (crypto-treasury clients, 22 companies supported as at May 2026), regional financial institutions, and overseas retail across South Korea, Vietnam, Cambodia, Thailand, Indonesia, Germany, Russia, New Zealand, Australia and Singapore.

Revenue$12.7B
Employees18,669
Market Cap$14.0B
Founded1999
Tokyo, Japan
Motilal

Motilal Oswal Financial Services Ltd

Premium
Information Technology

Motilal Oswal Financial Services is the holding company of one of India's few genuinely integrated, founder-controlled capital markets groups, and describes itself as the largest integrated capital market player in the country on the basis of net worth among non-bank peers. It operates a deliberate "twin-engine" architecture explicitly modelled on Berkshire Hathaway: five operating franchises — asset management, private wealth, retail wealth and broking, institutional equities and investment banking, and affordable housing finance — funded and supported by a large proprietary treasury book that has compounded at roughly 40% annually since FY2014 and now exceeds ₹10,000 crore. The strategic thrust since FY2023 has been a decisive rotation away from cyclical brokerage toward annuity revenue: annual recurring revenue reached 66% of net revenue in Q1FY27 versus 55% in FY2022. The group has never raised external equity since its 2007 IPO, has executed three buybacks, pays out roughly 20% of profits, and carries the highest long-term rating (AA+) available to a domestic non-bank capital markets firm. | Metric | FY2023 | FY2024 | FY2025 | FY2026 | Q1FY27 | |---|---|---|---|---|---| | Group employees (approx.) | 7303 | 10000 | 8900 | 12500 | 12600 | | MOFSL standalone employees | — | — | — | 7616 | — | *Note on the series: the group headcount is disclosed only intermittently and on inconsistent bases. The company states the group crossed 10,000 employees in calendar 2024, that FY2026 headcount of ~12,500 grew 41% year on year (implying roughly 8,900 at March 2025), and that headcount exceeded 12,600 at June 2026. The 41% FY2026 growth rate and the "crossed 10,000 in 2024" milestone are not fully reconcilable, most likely because of differing definitions of on-roll versus total workforce; both company statements are reproduced here without adjustment. The FY2023 figure of 7,303 is a secondary-source datum and is not corroborated by a primary filing.* --- ### What the company does MOFSL is a non-deposit-taking, systemically-relevant financial holding company registered as an NBFC with the Reserve Bank of India, and simultaneously a SEBI-registered stock broker, depository participant, research analyst, portfolio manager, AMFI-registered mutual fund distributor and IRDAI corporate agent. It operates directly (retail broking, institutional equities, distribution, margin lending against securities held on its own balance sheet, and the proprietary treasury book) and through 21 subsidiaries and step-down subsidiaries (asset management, alternates, private wealth, housing finance, NBFC lending, custodial services, IFSC and offshore vehicles). The registration stack is itself a barrier to entry and worth enumerating, because it defines the perimeter of what the group can sell: MOFSL holds INZ000158836 (BSE/NSE/MCX/NCDEX broking), IN-DP-16-2015 (CDSL and NSDL depository participant), INH000000412 (research analyst), ARN 146822 (AMFI mutual fund and SIF distributor), APRN00233 (APMI), and CA0579 (insurance corporate agent). Motilal Oswal Asset Management Company holds INP000000670 for portfolio management alongside its mutual fund licence. ### The company's own characterisation In its FY2025-26 Board's Report the company states that it, together with its subsidiaries, "offers a diversified range of financial products and services such as institutional equities, asset management business, housing finance, private equity, private wealth management, investment banking, loan against securities and investment activities." Its investor communications frame the enterprise around two propositions. The first is the twin-engine model: "Engine #1" comprises the operating businesses, each run by a professional CEO; "Engine #2" is the treasury book, which the company describes as providing "synergy, liquidity and stability," acting as collateral support for group borrowings, absorbing shocks, funding entry into adjacencies, and removing any need to raise external equity. The second is the financialisation thesis: management repeatedly cites a projected rise in cumulative Indian household savings from roughly USD 10 trillion accumulated over the past 25 years to more than USD 100 trillion over the next 25, together with a rising equity share of household assets (currently 6.8% of a USD 14.5 trillion household asset pool). ### Independent characterisation Stripped of the Berkshire framing, MOFSL is best understood as three businesses of very different economic character stapled to a large equity portfolio. The first is a fee-on-assets manufacturer — the AMC, the alternates platform and private wealth — which now produces the majority of group operating profit (55% in Q1FY27), earns operating returns on allocated equity of 37%, and carries genuine operating leverage because incremental AUM arrives at high incremental margin. This is the part of the group that deserves an asset-manager multiple. The second is a transaction-and-balance-sheet business — retail broking, distribution and margin trade funding — which absorbs the largest slice of allocated net worth (₹5,401 crore of ₹11,190 crore operating equity at June 2026) but earns only 12–16% on it. Brokerage revenue in absolute terms actually fell in FY2026 (₹1,395 crore against ₹1,496 crore in FY2025), and the segment is being progressively re-based on net interest income from the MTF and LAS books rather than on commissions. Management's own concall commentary acknowledges share loss in cash and F&O volumes to digital brokers. The third is a small, well-capitalised affordable housing lender (₹6,164 crore AUM, CRAR 37.8%, ROE 8.0% annualised in Q1FY27) that is sub-scale, earns below its cost of capital, and has periodically been the subject of divestment speculation. Over all three sits a proprietary book of ₹10,482 crore, which is the single largest driver of reported earnings volatility. In FY2026 it swung reported profit from an operating ₹2,360 crore to a headline ₹2,043 crore of total comprehensive income; in Q1FY27 it added ₹904 crore to a ₹609 crore operating result. Investors are effectively buying a fee business, a levered broker, a small HFC, and a leveraged long-India equity fund in a single wrapper. ### Revenue model | Revenue stream (% of net operating revenue) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---|---|---| | Management & advisory fees | 20 | 19 | 18 | 19 | 21 | 26 | | Distribution fees | 11 | 11 | 11 | 11 | 15 | 16 | | Net interest income | 27 | 29 | 32 | 31 | 31 | 31 | | Brokerage revenues | 37 | 36 | 34 | 34 | 28 | 23 | | Other operating revenues | 4 | 5 | 4 | 4 | 4 | 4 | | Total net operating revenue (₹ crore) | 1940 | 2623 | 2947 | 3943 | 5178 | 5908 | | Share of annual recurring revenue (%) | 56 | 55 | 56 | 55 | 54 | 60 | MOFSL does not sell products or licences; it sells intermediation, advice, manufacturing and credit. Its revenue architecture, as disclosed, breaks into five streams. In Q1FY27 the mix moved further: management and advisory fees 30%, distribution fees 11%, net interest income 32%, brokerage 22%, other 4%, on net operating revenue of ₹1,538 crore, with ARR share at 66% and fee-plus-NII at 78% of net revenue. Net revenue is calculated by the company after excluding commission expenses, interest expenses and intercompany adjustments; it is therefore not comparable to the ₹9,416 crore of statutory total income. ### Value chain position The group occupies an unusually wide span of the Indian savings value chain: manufacture (mutual funds, ETFs, PMS, AIFs, private equity, real estate and private credit funds), advice (institutional research on 384 companies, retail research, private wealth advisory under the "Delphi" discretionary mandate), distribution (own branches plus 7,610 external wealth managers and business partners across 550+ cities and 2,500+ business locations, with 95%+ pin-code coverage), execution (broking across cash, F&O, currency and commodities on NSE, BSE, MCX and NCDEX), financing (MTF, LAS, housing loans), custody and depository (CDSL and NSDL DP, plus Motilal Oswal Custodial Services), and primary market origination (IPOs, QIPs, block deals, InvIT issuance, M&A advisory). This vertical integration is the group's principal structural advantage and also its principal conflict-management burden: the same platform manufactures the product, advises on it, distributes it and lends against it. The cross-sell ratio on the ~5.7 million broking client base is currently around 18% (management describes it as "below 15%" in the Board's Report and "~18%" in the Q1FY27 deck — a discrepancy noted below), which management frames as the group's largest untapped internal opportunity. ### Customer types and end-markets | Client segment | Definition / threshold | Served by | Scale disclosed | |---|---|---|---| | Retail / mass affluent | Individual investors and traders | Wealth Management (broking, distribution, MTF, LAS); AMC via MFDs and digital | ~5.7 mn broking clients; ~1.5 mn active; ~10.1 mn AMC folios; per-client AUM ~₹2 mn | | Emerging HNI | Financial wealth ₹5–50 crore | Private Wealth Management | Part of ~250,000-strong TAM cohort | | HNI | Financial wealth ₹50–500 crore | Private Wealth Management | Part of ~25,000-strong TAM cohort | | UHNI / family offices / promoters | Financial wealth ₹500 crore+ | Private Wealth Management; co-investments; Foundation philanthropy desk | 400+ Hurun UHNI families; 9,485 "relevant families" (≥₹1 crore AUM, ex-custody) | | Domestic and foreign institutions | Mutual funds, insurers, FPIs, sovereign funds | Institutional Equities | 910+ institutional clients | | Corporates and issuers | Listed and pre-IPO companies | Investment Banking | 52 deals in FY2026 | | Affordable-housing borrowers | Tier II/III and extended-suburb salaried and self-employed | Motilal Oswal Home Finance | ₹6,164 crore AUM; retail ₹5,192 crore | The addressable market management points to for private wealth alone is ₹240 trillion of investible wealth across the three HNI tiers, growing at a mid-teens CAGR to 2029 on a top-tier consulting firm's projections cited in the Q1FY27 deck.

Revenue$1.1B
Employees12,500
Market CapN/A
Founded1987
Maharashtra, India
Disc

Disc Medicine Inc

Premium
Information Technology

Disc Medicine is a Watertown, Massachusetts–based clinical-stage biopharmaceutical company built around a single, unusually coherent scientific thesis: that a small number of fundamental control points in red-blood-cell biology — heme biosynthesis and iron homeostasis, mediated by hepcidin — can be pharmacologically tuned in either direction to treat a wide spectrum of haematologic disease. The company operates an in-licensing-and-develop model rather than a discovery-platform model, having assembled its three clinical assets from Roche (bitopertin), AbbVie (selcodebart/DISC-0974 and DISC-0998) and Mabwell Therapeutics (DISC-3405). It has no products approved and no revenue. Its near-term valuation is dominated by a single binary: the Q4 2026 topline readout of the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, which follows a February 2026 Complete Response Letter. Behind that sits a genuine second act in myeloproliferative neoplasms. With approximately $718 million of liquidity at 30 June 2026 and runway into 2029, Disc is unusually well-capitalised for its stage. --- **What the company does.** Disc Medicine discovers, in-licenses, develops and intends to commercialise novel therapeutics for serious haematologic diseases. In the company's own words, repeated verbatim in every press release and in the Compensation Discussion and Analysis of the 2026 proxy statement: *Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.* **Independent characterisation.** Disc is best understood not as a discovery platform company but as a mechanism-directed asset aggregator with deep domain expertise in a single organ system. Management — drawn heavily from Acceleron Pharma, which built a comparable franchise around TGF-β superfamily biology in haematology before its $11.5 billion sale to Merck — has applied a repeatable playbook: identify a de-risked or partially de-risked molecule whose originator has deprioritised it, secure global rights at modest upfront cost with back-loaded milestones, and redirect it into a rare or under-served haematologic indication where the biology is mechanistically obvious and the regulatory path is short. All three clinical assets were sourced this way. Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that Roche advanced through large schizophrenia trials — generating a safety database of more than 4,000 clinical trial participants — before abandoning the CNS indication; Disc licensed it in May 2021 and repositioned it against erythropoietic porphyrias, where reducing glycine supply to developing erythroblasts throttles the accumulation of the toxic photoactive intermediate protoporphyrin IX (PPIX). Selcodebart (DISC-0974), an anti-hemojuvelin monoclonal antibody in-licensed from AbbVie, suppresses hepcidin to liberate iron in anaemia of inflammation. DISC-3405, an anti-TMPRSS6 (matriptase-2) monoclonal antibody in-licensed from Mabwell Therapeutics in January 2023, does the mirror image — inducing hepcidin to restrict iron in diseases of excess erythropoiesis or iron overload. The elegance of the portfolio is that DISC-0974 and DISC-3405 are pharmacological opposites acting on the same axis, giving Disc coverage of both hepcidin-deficient and hepcidin-excess disease states. **Business model and revenue model.** Disc has generated no product, service, subscription or licensing revenue in any fiscal year reported. Its consolidated statements of operations show no revenue line whatsoever for FY2021 through FY2025 and for the six months ended 30 June 2026. The company is financed entirely by equity issuance, supplemented by a term-loan facility from Hercules Capital. The intended revenue model is direct commercialisation: Disc retains worldwide rights to bitopertin and has already built marketing, market access, medical science liaison and field sales infrastructure in the United States in anticipation of launch, a build-out the compensation committee credited as a 2025 corporate achievement. One small out-licensing arrangement exists — a December 2024 out-license of legacy Gemini intellectual property to Oak Bay Biosciences, Inc. — but it is immaterial to the investment case. **Value chain position.** Disc occupies the clinical development and (prospectively) commercial layers only. It owns no manufacturing. Drug substance and drug product are produced by contract development and manufacturing organisations; the 2025 corporate goals explicitly include "initiated CMC technology transfer to Phase 3 CDMO" for both DISC-0974 and DISC-3405, confirming an outsourced supply chain. Clinical trials are run through contract research organisations, a dependency the company identifies as a risk factor. Upstream, Disc is a licensee dependent on Roche, AbbVie and Mabwell for underlying rights; downstream, if approved, bitopertin would be distributed through specialty pharmacy and centre-of-excellence channels typical of ultra-rare disease. **Customer types and end-markets.** Ultimately: haematologists, hepatologists and dermatologists treating protoporphyria at porphyria centres of excellence; haematologist-oncologists treating myelofibrosis and polycythemia vera; and, in later-stage pipeline ambitions, gastroenterologists (anaemia of inflammatory bowel disease) and sickle cell disease specialists. Payers are commercial insurers and CMS in the US, and national reimbursement bodies in Europe. Management commentary at the Wells Fargo healthcare conference in September 2026 indicated a launch strategy focused on engaged, diagnosed patients and centres of excellence — the classic ultra-orphan concentration play.

RevenueN/A
Employees165
Market CapN/A
Founded2022
Massachusetts, US
Origin

Origin Energy Ltd

Premium
Information Technology

*Origin does not publish a precise year-by-year headcount in the results release; FY24 and FY25 figures reflect the company's consistent "more than 5,000 employees" disclosure and are flagged as approximate. The FY26 figure of "5,300-strong team" is drawn directly from the FY26 Annual Report.* Origin Energy is Australia's largest integrated energy company by retail customer accounts and, uniquely among domestic peers, a materially globalised business through minority stakes in two of the fastest-scaling franchises in the sector. Domestically it couples 4.94 million retail accounts with an 8.6 GW owned-and-contracted generation portfolio — including Australia's largest coal-fired station at Eraring, its largest thermal peaking fleet, and a 1.8 GW battery build-out — and a 27.5 per cent interest in Australia Pacific LNG, one of the lowest-cost coal-seam-gas-to-LNG projects globally. Layered on top is a 22.7 per cent economic interest in Octopus Energy, Europe's fifth-largest energy retailer with 19 million accounts, and the same interest in Kraken Technologies, a utility operating system contracted to 95 million accounts across more than 20 countries. The result is a hybrid: a cash-generative, fully franked domestic utility funding an option on the global digitalisation and electrification of energy retail. --- ### The company's own characterisation Origin states its purpose as "getting energy right for our customers, communities and planet" and its ambition as to "lead the energy transition through cleaner energy and customer solutions" (FY26 Annual Report, OFR §1 and §2). Management describes the business as "a leading integrated energy company" whose "earnings drivers are spread across the energy value chain" (FY26 Annual Report, OFR §2, Our Business Drivers). The FY26 Annual Report articulates three strategic pillars: *Unrivalled customer solutions*, *Accelerate renewables and cleaner energy*, and *Deliver reliable energy through the transition*, mapped respectively to three decarbonisation priorities: enable customers to decarbonise, grow the portfolio of renewable and cleaner energy, and reduce emissions from existing operations. ### Independent characterisation Origin is best understood as four economically distinct businesses stapled into one listed vehicle, only two of which are consolidated: **(i) An integrated Australian energy utility (consolidated).** Origin buys, generates and sells electricity and gas into the National Electricity Market and east-coast gas market. The economics are not those of a regulated network but of a vertically integrated merchant retailer: gross profit is the spread between customer tariffs (largely reset annually via the Default Market Offer and Victorian Default Offer, or every one to three years for business contracts) and the delivered cost of energy from a portfolio of owned generation, power purchase agreements, swaps, caps and pool purchases. Management describes the deliberate structural posture as "typically to remain short" of energy, meaning falling in-year pool prices are upside and rising prices are downside, while the portfolio is set up to be balanced or long during high-price capacity events above A$300/MWh (FY26 Investor Presentation, slides 50–51). This is the central mechanic of Origin's earnings and the single most important thing to understand about the equity. **(ii) An upstream gas and LNG interest (equity-accounted).** Origin holds 27.5 per cent of Australia Pacific LNG and is its upstream operator. This is a commodity-price-taking, cash-distributing asset: around 80 per cent of APLNG's FY26 gas volume was sold as LNG, of which 91 per cent under long-term oil-linked contracts (FY26 Annual Report, OFR §2). Because the interest is equity-accounted, APLNG contributes to underlying EBITDA and underlying profit but not to consolidated revenue; the cash reaches Origin as dividends recorded in investing cash flow (A$911 million fully franked in FY26). **(iii) A minority interest in a global energy retailer (equity-accounted).** Origin holds 22.7 per cent of Octopus Energy Topco Limited: 19 million retail accounts, of which 14.8 million in the United Kingdom (26 per cent market share) and 4.1 million outside it, plus an Energy Services arm doing heat pump, solar, battery and EV charger installation and a 49,000-vehicle EV leasing fleet. **(iv) A minority interest in an enterprise software platform (equity-accounted).** Following legal separation on 17 June 2026, Origin holds 22.7 per cent of Kraken Technologies Global Group Limited (19.6 per cent direct, 3.1 per cent indirect through Octopus). Kraken is a subscription software business: FY26 revenue of £300 million, 19 per cent growth, 75 per cent subscription gross margin, contracted annual recurring revenue up 44 per cent, gross retention above 99 per cent (FY26 Investor Presentation, slides 25–26). This is the only genuinely software-economics asset in the group. ### Revenue model mix | Revenue construct (A$m) | FY2025 | FY2026 | |---|---|---| | Energy Markets segment revenue | 16745 | 15262 | | Less pool revenue from internal generation | 3097 | 1664 | | Less gross settled PPAs | 3 | 1 | | Less other reclassifications | 79 | 26 | | Energy Markets total customer revenue | 13567 | 13571 | Origin's consolidated revenue is overwhelmingly commodity sales, not subscription or licensing. Of FY26 segment revenue of A$15,569 million, A$15,262 million (98 per cent) was Energy Markets and A$307 million was Integrated Gas – Other (FY26 Appendix 4E; segment note). Within Energy Markets, customer revenue of A$13,571 million reconciles from segment revenue after deducting A$1,665 million of pool and other revenue from internal generation (FY26 Investor Presentation, slide 46). The striking observation is that customer revenue was flat year on year (A$13,567 million to A$13,571 million) while segment revenue fell 9 per cent — the entire decline is internal generation pool revenue, a mechanical consequence of lower wholesale prices and 1.3 TWh less owned and contracted generation, not customer attrition. Analysts who read the headline 10 per cent group revenue decline as a demand problem are misreading it. Subscription and licensing economics exist only at the look-through level via Kraken. Service revenue (Energy Services and Internet) contributed A$53 million of EBITDA in FY26. ### Value chain position and customers Origin occupies fuel supply, transportation, generation and trading, and customer solutions. It does not own networks. Customer types span mass-market residential (2.70 million electricity, 1.11 million gas), community energy services (208,000 electricity, 276,000 gas — embedded networks and apartments), small-to-medium business, and large commercial and industrial customers served through the Origin Zero brand. End-markets served are Australian households, Australian business and industry, the east-coast wholesale gas market, and — via APLNG — LNG buyers in North Asia, principally Sinopec (approximately 7.6 mtpa to 2035) and Kansai Electric (approximately 1.0 mtpa to 2035).

RevenueN/A
Employees5,300
Market CapN/A
Founded2000
Barangaroo, Australia
NRGEnergy

NRG Energy Inc

Premium
Information Technology

NRG Energy is the only large-scale North American power company that has deliberately built its identity around the customer relationship rather than the generating asset. It sells electricity, natural gas and smart-home services to roughly eight million residential customers — six million retail energy, two million smart home — alongside a leading business-to-business power and gas franchise and, since January 2026, a 6 GW commercial and industrial demand-response platform. The January 2026 acquisition of thirteen gigawatts of natural gas generation from LS Power doubled owned capacity to approximately 25 GW and reversed a decade of asset-light drift, converting NRG into an integrated generator-retailer positioned squarely against data-centre load growth in ERCOT and PJM. The result is a hybrid: a subscription-like smart-home annuity, a commoditised but sticky retail book, and a newly enlarged merchant generation fleet whose value is highly levered to power-demand growth and capacity-market design. --- ### The company's own characterisation The FY2025 Form 10-K opens with a description that is worth reproducing in substance because it defines management's own framing. NRG describes itself as serving electricity, natural gas and smart-home technology solutions to approximately eight million residential customers — six million retail energy and two million smart home — in addition to large commercial and industrial, data centre and wholesale customers. It operates under the brand names NRG, Reliant, Direct Energy, Green Mountain Energy and Vivint. As of 31 December 2025 the core power and natural gas business consisted of approximately 12 GW of competitive power generation, primarily in Texas, and a natural gas portfolio serving approximately 1,900 MMDth annually. The company sold 154 TWh of electricity and 1,857 MMDth of natural gas in 2025. At the end of 2025 it had recurring electricity and/or natural gas sales in 25 U.S. states, the District of Columbia and 8 Canadian provinces, while Vivint Smart Home served customers in all 50 U.S. states and the District of Columbia. Management asserts that NRG's retail brands collectively hold the largest share of competitively served residential electric customers in Texas, and that NRG is a leading business-to-business provider of power and natural gas in North America. Management's stated strategy is to maximise shareholder value by delivering integrated energy and smart-home solutions supported by an owned generation fleet and a diversified supply strategy, with a "customer-first platform that promotes reliability and affordability." The four named growth vectors are: demand response and virtual power plants; completion of the Texas Development Projects; long-term contract-backed generation supported by partnerships with equipment manufacturers and EPC contractors; and increasing capacity at existing facilities. ### Independent characterisation NRG is best understood as three businesses with materially different economics, welded together by a single supply and hedging function. **First, an integrated generation-and-retail business in ERCOT.** This is the historical core and remains the largest single profit pool. In Texas the generation fleet is fully integrated with retail load. The 10-K is explicit about why this matters: supplying a portion of retail customers from owned assets reduces the need to transact with intermediaries, producing more stable earnings and cash flows, lower transaction costs, less credit exposure and — critically — a structural reduction in actual and contingent collateral through offsetting positions. The collateral point is not cosmetic; NRG's cash-flow statement shows swings in collateral deposits of $1.8 billion (2023 outflow) and $245 million (2024 inflow), which dwarf most operating variances. Vertical integration is, in substance, a working-capital strategy as much as a margin strategy. **Second, a wide-footprint retail energy business outside Texas.** In the East, West and Canada, NRG is substantially a retailer competing against incumbent utilities that still provide default service. Margins are thinner, customer acquisition costs are real, and regulatory risk is idiosyncratic and state-by-state — Maryland's Senate Bill 1, which imposed a price cap tied to a trailing twelve-month utility rate average and terminated grandfathering of existing contracts as of 31 December 2025, is the clearest recent example of how a single state legislature can impair a retail book. The East segment nonetheless carries the largest revenue line (FY2025: $14.3 billion) because it contains the very large business-to-business natural gas franchise inherited from Direct Energy — 1,549,286 MDth of Business–East gas volume in 2025, more than 80% of NRG's total gas load. **Third, Vivint Smart Home — a subscription business inside a commodity company.** This is the most economically distinct piece. Vivint generated FY2025 revenue of $2,144 million and Adjusted EBITDA of $1,092 million, an Adjusted EBITDA margin of approximately 51%, versus 17% for Texas and 7% for East. Its economics are those of a hardware-subsidised subscription: customers are acquired at negative initial cash flow (gross capitalised contract costs were $970 million in 2025, against $846 million in 2024), then monetised over an average customer lifetime of approximately nine years. The platform supported more than 37 million connected in-home devices at year-end 2025, averaging roughly 16 devices per household. Ending Vivint subscribers grew from 2,111 thousand (2023) to 2,226 thousand (2024) to 2,419 thousand (2025). **Revenue model mix.** NRG does not disclose a formal product/service/subscription/licensing split. Directionally, based on segment revenue for FY2025: commodity sales (retail and wholesale electricity and gas) represented approximately 93% of revenue; smart-home subscription and equipment revenue approximately 7%. On an Adjusted EBITDA basis the picture inverts materially — Vivint contributed 27% of consolidated FY2025 Adjusted EBITDA on 7% of revenue. There is no licensing revenue of consequence. This mix asymmetry is the single most important structural fact about NRG's earnings quality and is frequently underweighted by investors anchoring on revenue. **Value-chain position.** NRG occupies the generation and retail supply ends of the electricity value chain and deliberately does not own transmission or distribution. The 10-K is explicit that the company depends on third-party transmission, distribution, pipeline and storage infrastructure it does not control, and that in certain markets it may bear congestion costs where load is not co-located with retail sales obligations. In natural gas, the scale of the operation extends from the wellhead, through a producer-services business, to end-use customers. **Customer types and end markets.** Residential (Home) customers typically contract for terms of one month to five years; Business customers for one to five years with extended terms available. Business and commercial and industrial products include system power, natural gas, demand response, distributed and backup generation, energy storage, energy management, renewable and low-carbon products, carbon management, energy efficiency and — the newest and strategically most significant — "bring your own power" (BYOP) arrangements for large loads. No single customer represented more than 10% of consolidated revenue in FY2025.

Revenue$30.7B
Employees16,702
Market CapN/A
Founded1992
United States, North America
Titan

Titan Company Ltd

Premium
Information Technology

Titan Company Limited is India's largest and most profitable branded lifestyle retailer, and the single most consequential force in the formalisation of the Indian jewellery market. Structured as a 42-year-old joint venture between the Tata Group and the Government of Tamil Nadu's industrial development arm, Titan converted a quartz watch manufacturing licence into a multi-category consumer franchise anchored on Tanishq — a brand that has made purity assurance, transparent making charges and exchange liquidity the default consumer expectation in a category historically dominated by unorganised family jewellers. Roughly nine-tenths of revenue now comes from jewellery, with watches, eyecare, fragrances, ethnic wear, handbags and a precision-engineering subsidiary forming a portfolio of adjacencies at varying stages of maturity. The January 2026 acquisition of Damas Jewellery marks Titan's transition from a diaspora-led export story to a genuine Gulf regional operator. Titan trades at a persistent and substantial valuation premium to every listed Indian consumer peer. | Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Employees (BRSR "employees" category, count) | 8680 | not separately extracted | 8353 | | Workers (BRSR "workers" category, count) | not separately extracted | not separately extracted | 11805 | | Total permanent workforce (count) | not separately extracted | not separately extracted | 20158 | | Women as % of employees | not separately extracted | not separately extracted | 27 | | Women as % of workers | not separately extracted | not separately extracted | 29 | *Source: Titan BRSR FY2025-26 (filed with stock exchanges, reported July 2026), which discloses 8,353 employees and 11,805 workers at year-end with women at 27% and 29% respectively; Tracxn / MCA filings for the FY2024 figure of 8,680. Titan's three-year headcount series is not disclosed on a consistent single basis across the reviewed sources; the FY2024 and FY2026 figures use different classification conventions and should not be read as a like-for-like trend. Note also that Titan's total ecosystem employment is materially larger than the permanent workforce because the retail network is predominantly franchise-operated.* ### Market capitalisation and price | Metric | Value | As at | |---|---|---| | Share price (INR) | 5020 | 4 September 2026 close | | Market capitalisation (INR crore) | 445669 | 4 September 2026 | | Market capitalisation (INR crore) | 351000 | 31 March 2026 (per Titan Q4FY26 investor presentation) | | 52-week high (INR) | 5187 | trailing twelve months to 4 September 2026 | | 52-week low (INR) | 3303 | trailing twelve months to 4 September 2026 | | Trailing P/E (x) | 76.4 | 4 September 2026 | | Price / book (x) | 28.4 | 4 September 2026 | | Book value per share (INR) | 177 | 31 March 2026 | | Dividend yield (%) | 0.30 | 4 September 2026 | *Source: Screener.in consolidated data page for Titan Company Ltd (data sourced from BSE/NSE filings, retrieved 6 September 2026); Titan Q4FY26 investor presentation dated 8 May 2026 for the 31 March 2026 market capitalisation.* --- ### What the company does Titan Company Limited designs, manufactures, sources, markets and retails branded lifestyle products across five broad consumer categories — jewellery, watches and wearables, eyecare, fragrances and fashion accessories, and ethnic apparel — and additionally operates a business-to-business precision engineering and automation business through a wholly owned subsidiary. The company's own characterisation, carried consistently in its annual reports, is that it is "among India's most respected lifestyle companies," with "established leadership positions in the Watches, Jewellery and Eyewear categories led by its trusted brands and differentiated customer experience," and that it was "founded in 1984 as a joint-venture between TATA Group and Tamilnadu Industrial Development Corporation (TIDCO)" *(Titan Annual Report, carried forward across editions; quoted via Screener.in company description)*. Titan's stated corporate vision is "We create elevating experiences for the people we touch and significantly impact the world we work in" *(Titan BRSR FY2025-26)*. ### Independent characterisation Titan is best understood not as a jewellery manufacturer but as a branded retail and trust-arbitrage business built on top of a commodity. The economic substance of the jewellery division is that Titan buys gold (largely on a gold-on-loan / metal-loan basis that transfers commodity price risk away from the balance sheet), converts it into designed, hallmarked, warranted product, and sells it through an owned-and-franchised retail estate at a making charge and studded-mix margin over the metal value. The gross metal value passes through the P&L as revenue but generates almost no margin; essentially the entire economic profit of the jewellery division is earned on making charges, the studded (diamond) mix, and the difference between organised and unorganised trust premia. This is why Titan reports a ~10% EBIT margin on ₹67,602 crore of jewellery income rather than the 30-50% margins typical of branded consumer companies, and why the correct comparison set is organised retailers rather than FMCG. Three structural consequences follow, and they define the investment case: 1. **Revenue is levered to gold prices as well as volume.** In an environment of sharply rising bullion (FY2026 saw record rupee gold prices), Titan's reported revenue growth substantially overstates underlying unit and buyer growth. Management has repeatedly disaggregated this: in Q1FY2027, for example, buyer growth was in "early double digits" while average ticket size grew in "high double digits" *(Titan Q1FY27 business update, July 2026)*. Analysts and management alike therefore track buyer growth and like-to-like (L2L) growth as the true operating signals. 2. **Working capital is the binding constraint on growth, not capital expenditure.** Inventory days ran at 222 in FY2026 against payables of 15 days, producing a cash conversion cycle of 211 days *(Screener.in ratio extract from filings)*. Every incremental rupee of jewellery revenue requires an incremental rupee of gold inventory. This is why Titan's borrowings have risen from ₹7,275 crore (FY2022) to ₹30,621 crore (FY2026) despite capital expenditure never exceeding roughly ₹900 crore in a year — the debt funds gold, not stores. 3. **The retail model is capital-light at the store level.** A very large share of Tanishq's network operates on a franchise basis, with Titan owning the inventory and brand and the franchisee owning the real estate and store capex. This is what permits a 3,600-plus store network on a fixed asset base of ₹6,878 crore. ### Revenue model mix Titan's revenue is overwhelmingly product sale revenue. There is essentially no subscription revenue, and licensing revenue is inbound rather than outbound — Titan pays royalties to license international watch brands (Tommy Hilfiger, Police, Ducati, Anne Klein, Aigner, Kenneth Cole) rather than earning licence income. The exceptions to the pure-product model are: **Golden Harvest / savings schemes:** Tanishq and CaratLane operate instalment-based purchase schemes that function as a form of pre-committed customer financing and are a meaningful driver of footfall and conversion. - **Encircle loyalty programme**, a cross-brand customer data and retention asset. - **TEAL (Titan Engineering & Automation Limited)**, which earns B2B project and component revenue in automation machine building and aerospace/defence precision manufacturing — a genuinely different revenue model (order-book driven, project-recognised) embedded inside a consumer company. - **Bullion and digi-gold sales**, which are pass-through, near-zero-margin metal sales that Titan explicitly strips out of its management reporting. ### Value chain position Titan occupies an unusually wide span of the value chain for a retailer: it operates 11 manufacturing and assembly facilities, designs in-house through a Chief Design Officer function, controls its brand portfolio, and controls the customer relationship through owned and franchised exclusive brand outlets plus e-commerce. In watches it is a genuine vertically integrated manufacturer (movements, cases, assembly). In jewellery it combines in-house karigar (craftsman) manufacturing with a large sourced-supplier base. It does not mine gold or diamonds and does not operate diamond cutting and polishing at scale — the upstream is sourced. ### Customer types and end-markets Titan sells almost entirely business-to-consumer, to Indian households across four defined price tiers that the company maps explicitly in its investor materials: luxury (Zoya, Helios Luxe, Nebula), premium (Tanishq, Titan flagship, Xylys, Favre-Leuba), mid-market (Mia, CaratLane, Titan Eye+, SKINN, Taneira, IRTH) and mass-market (Sonata, Fastrack) *(Titan Q4FY26 investor presentation)*. End-markets served are: bridal and wedding jewellery (the dominant demand pool), daily-wear and gifting jewellery, timekeeping and fashion watches, smart wearables, prescription and sun eyewear, fragrances, women's handbags, women's ethnic dresswear, and — through TEAL — industrial automation and aerospace/defence components for global OEMs.

Revenue$10.1B
Employees8,353
Market CapN/A
Founded1984
Tamil Nadu, India

Page 121 of 482

1…120121122…482

Page 121 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo